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52 Introduction
2.1 Cross-­presentation
2.1.1 General mechanisms
CD8+ T cells respond to their specific antigen in the context of Major Histo-­‐Compatibility
(MHC)-­‐Class-­‐I molecules, which are expressed by all nucleated cells and allow for a constitutive
display of endogenous antigens. However, activation of naïve CD8+ T cells requires more than
solely antigen-­‐recognition, referred to as signal 1 (1). The second prerequisite is that T cells
receive additional costimulatory signals that are provided by dendritic cells (DCs) under
inflammatory conditions. These additional signals confer cytolytic capacity to the CD8+ T cell,
which can then subsequently destroy infected or altered body cells that display the specific T
cell antigen.
As naïve CD8+ T cells depend on both antigen and costimulatory signals for their activation,
there has to be a way to induce CD8+ T cell responses if DCs are not infected or altered
themselves. A second pathway of antigen processing termed cross-­‐presentation allows the
presentation of internalized antigens by professional antigen-­‐presenting cells on MHC-­‐class-­‐I.
This pathway is a crucial extension to the classical pathway in preventing the immune escape
of viruses that do not infect DCs and thereby might circumvent CD8+ T cell activation due to a
lack of synchronous presentation of costimulatory molecules and viral antigens in the context
of MHC-­‐class-­‐I. Bevan et al. first described the cross-­‐priming in 1976 (2) after they immunized
mice with allogenic cells and examined the MHC-­‐restriction of the induced CD8+ T cell
response. The immunization generated CD8+ T cells that were restricted to both donor and,
surprisingly, host MHC-­‐class-­‐I molecules. The latter was only possible if the host cells acquired
donor cellular antigens and processed them on MHC-­‐class-­‐I to CD8+ T cells. This antigen
presentation pathway has since been termed cross-­‐presentation. When it results in CD8+ T cell
immunity it is referred to as “cross-­‐priming” whereas the induction of tolerance is referred to
as “cross-­‐tolerance”.
The cellular mechanisms enabling the cross-­‐presentation pathway are not yet fully
understood. It is evident that cross-­‐presentation requires that ingested antigens circumvent
lysosomal degradation and MHC-­‐class-­‐II-­‐loading and are instead processed by the MHC-­‐class-­‐I-­‐
6loading machinery that is typically located in the endoplasmic reticulum (ER). However, recent
studies suggest that loading of soluble and particulate antigen on MHC-­‐class-­‐I molecules does
not necessarily occur in the ER, but rather in specialized endocytic and phagocytic
compartments (3). Burgdorf et al. (4) described that certain antigens, which are taken up via
distinct endocytic receptors (such as C-­‐type lectins and Fc receptors) remain in so-­‐called stable
early endosomes that do not develop into late endosomes. Cross-­‐presentation of these
antigens is favored by the presence of insulin-­‐regulated aminopeptidase (IRAP), which was
found to degrade antigens to a peptide length that is appropriate for loading on MHC-­‐class-­‐I
molecules (5). Soluble antigens that are taken up by different means are directed into late
endosomes where they enter the MHC-­‐class-­‐II-­‐loading machinery. Thus, soluble antigens
intended for cross-­‐presentation are spatially separated from other antigens at an early stage
(6).
For particulate antigens, it has been suggested that cross-­‐presentation occurs in phagosomes,
which contain molecules of the MHC-­‐class-­‐I-­‐loading machinery. However, it is currently
unclear and a matter of debate how these molecules reach the phagosomes and how this
process is regulated (7).
2.1.2 Cell types capable of cross-­presentation
The cell type best known for its ability to cross-­‐present in mice is the CD8+ DC (8). CD8+ DCs
represent a tissue-­‐resident DC subset that also express CD24+, CD205+ and Clec9A+, which are
useful markers to better define this population (8). Human DCs do not express CD8 but the
equivalent cell type to mouse CD8+ T cells has been described to be Clec9A+ DNGR1+ BDCA3+
XCR1+ (9,10).
Although DCs seem to be best suited for cross-­‐presentation, other cell types can also cross-­‐
present, including B cells (11), human γδ T cells (12), neutrophils (13), macrophages (14) and
liver sinusoidal endothelial cells (15).
72.2 DC licensing
2.2.1 Requirement for help
It is essential that CD8+ T cell activation is tightly regulated in order to avoid destruction of
healthy self-­‐cells. One mechanism that regulates T cell activation is the need for several
distinct signals to be provided by the DC in addition to antigen-­‐presentation. The different
signals required for T cell activation have been termed Signal 1, 2 and 3 (1,16,17):
Signal 1: Specific antigen in context of MHC-­‐class-­‐I molecules.
Signal 2: Costimulatory molecules of the B7 family for example CD80/86 (bind to CD28 on the
T cell) or of the tumor necrosis factor (TNF) receptor family for example CD40 (binds to CD40L)
Signal 3: Cytokines like IL-­‐12 and type-­‐I IFN, proposed to enable optimal effector functions and
memory responses.
Under homeostatic conditions, DCs take up antigens and present them on MHC-­‐molecules, but
cannot provide costimulatory signals, leading to T cell deletion and cross-­‐tolerance. Only under
inflammatory conditions do they become potent inducers of CD8+ T cell immunity by
upregulating costimulatory molecules and producing cytokines, thereby reaching a “mature”
state (18). Stimulation through Pattern Recognition Receptors (PRRs) that indicate the
presence of a pathogen can lead to upregulation of costimulatory molecules, but it seems that
these signals are not essential to render the DC capable of cross-­‐priming. The DC can become
activated in the absence of signals from pathogens or infected cells but instead require signals
from antigen-­‐specific CD4+ T cells (19,20).
2.2.2 Classical licensing via CD4+ T helper cells
Bennett et al. described in 1998 that efficient induction of cytotoxic T cell responses depends
on the previous activation of a DC by an antigen-­‐specific CD4+ T cell (21). This concept was
termed “cognate licensing”, indicating that the DC presents the same antigen on MHC-­‐class-­‐II
to the CD4+ T cell and on MHC-­‐class-­‐I to the CD8+ T cell. This prerequisite for complete DC
maturation functions as a “second opinion” about the relevance of the presented antigen and
helps to reduce the risk of activating autoreactive CD8+ T cells. Although autoreactive T cells
are present in the periphery despite negative selection in the thymus, an encounter of the
antigen-­‐presenting DC with a CD4+ T cell and a CD8+ T cell that are specific for the same self-­‐
antigen seems unlikely.
8A crucial feature of T cell help seem to be CD40L / CD40 interactions that result in upregulation
of adhesion-­‐ and costimulatory molecules and induction of cytokines like IL12 by the DC (22).
Although the requirement for T cell help has been described in several models, other reports
showed help-­‐independent CD8+ T cell responses. This inconsistency has been resolved by
studies that showed that primary CD8+ T cell responses can be functional even in the absence
of help, but that there is a requirement for CD4+ T cell help for the generation of functional
memory CD8+ T cells (23,24).
2.2.3 Alternative NKT cell mediated licensing
The Natural Killer (NK) T cell ligand α-­‐galactosylceramide (αGalCer) has long been known for
its adjuvant effect in enhancing tumor resistance (25). Since 2003 several reports described
that the mechanism underlying this property might be based upon the fact that NKT cells can
substitute for CD4+ help and license DCs (26,27): αGalCer can be presented by a DC on the
MHC-­‐like molecule CD1d, and will be recognized by the invariant T Cell Receptor (TCR) of an
NKT cell. The recognition of its antigen activates the NKT cell to upregulate CD40L and to
rapidly produce cytokines. The activated NKT cell in turn induces upregulation of maturation
markers and cytokines by DCs (28,26). Similar to classical licensing, CD40 plays a crucial role in
the alternative licensing process as CD40-­‐deficient mice were unable to develop enhanced
CD8+ T cell responses although DCs upregulated maturation markers due to cytokine signals
(28).
9Figure 2.2.3 Cellular network activated by αGalCer. DCs present lipid antigens like αGalCer on the
MHC-­‐like molecule CD1d to NKT cells, leading to upregulation of CD40L and production of TH1 and TH2
cytokines by NKT cells. In turn, DCs are activated to produce IL12 and express costimulatory molecules.
Cytokines can then influence other cell types like NK cells, B cells and T cells. Modified from Bendelac
Ann Rev Immunol 2004.
2.2.3.1 NKT cells
NKT cells were originally defined as T cells co-­‐expressing an αβ – TCR and NK cell markers such
as CD161 (NK1.1) and CD94, but it has become apparent that this is a poor definition as the
expression of NK markers differs dependent on both developmental stage and activation state
of the NKT cell and some NKT cell subsets entirely lack expression of NK1.1 (29).
The NKT cell TCR differs in several ways from the “regular” TCR that αβ-­‐ T cells express: NKT
cells do not recognize peptide antigens in the context of MHC-­‐class I or II but instead are
activated by glycolipids in the context of the MHC-­‐like molecule CD1d (30). The “classical”
CD1d-­‐restricted NKT cells express a TCR that is composed of Vα14 Jα18 in mice and Vα24 Jα18
in humans and a very limited set of β chains, in mice Vβ8.2 or 7.2, in humans mainly Vβ11 (29).
Because of this invariability they are also referred to as “invariant” or iNKT cells, or type-­‐1 NKT
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cells in contrast to type-­‐2 NKT cells that do not express this semi-­‐invariant TCR. Only type-­‐1
NKT cells are reactive to the model antigen αGalCer and are therefore the focus of this thesis.
αGalCer, which was isolated from the marine sponge Agelas mauritanius as a potent adjuvant
for cancer therapy (31), is the first described and most potent NKT cell antigen. Since its
discovery, synthetic αGalCer derivatives have been generated, for example OCH that has a
truncated sphingosine chain and induces TH2-­‐like responses (32). Several other glycolipid
antigens have since been identified, including bacterial glycolipids like α-­‐galactosyl-­‐
diacylglycerol (αGalDAG) derived from Borrelia burgdorferi, GSL1´ derived from Sphingomonas
species (33,34), and mammalian glycolipids like isoglobotrihexosylceramide (iGb3) (35).
Figure 2.2.3.1 Structure of different NKT cell ligands. Structures of the synthetic NKT cell
ligand αGalCer and its analog OCH, the microbial agents aGalDAG (Borrelia Burgdorferi) and
GSL1´(Sphingomonas), and the mammalian glycosphingolipid iGb3.
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It has been a matter of some debate how NKT cell activation by self-­‐lipids could be prevented
under homeostatic conditions. Recently, Darmoise et al. (36) demonstrated that the enzyme
α-­‐Gal-­‐A inhibits accumulation of self-­‐lipids in lysosomes under steady-­‐state conditions,
thereby preventing efficient presentation to NKT cells. Under inflammatory conditions,
microbes inhibit α-­‐Gal-­‐A activity, allowing for presentation of self-­‐antigen and activation of
NKT cells. These findings are in line with a report byMattner et al. (37) that proposed that NKT
cells are not directly activated by gram-­‐negative bacteria like Salmonella, but are activated
through presentation of iGb3 by LPS-­‐activated DCs.
Several subsets of type-­‐1 NKT cells have been described. Mice have CD4+ and double negative
(DN) subsets but lack CD8+ NKT cells, which are found in humans. Additionally, one has to
discriminate between NK1.1+ and NK1.1− NKT cells, the latter including a newly identified
subset called NKT-­‐17 cells, which produce large amounts of IL-­‐17 (38). NKT cells are known for
their ability to secrete many different cytokines rapidly after their activation. The dual
production of both TH1 and TH2 cytokines, especially IL-­‐4 and IFNγ, is one hallmark of NKT cells
enabling them to regulate the quality of immune responses. Therefore, NKT cells are important
players in a broad spectrum of diseases including viral infections, malaria, cancer and
autoimmunity, and can either promote or suppress immune responses in a particular given
setting. Recently it was found that the cytokine profile of NKT cells differs considerably
depending upon their CD4 and NK1.1 expression and the organ that the NKT cell was isolated
from (38). This emerging heterogeneity in functional subsets might shed light on the seemingly
contradictory roles that NKT cells can play. Clarifying the role of individual subsets in the
particular disease setting might help to understand why NKT cells push immune responses in a
certain directions.
2.3 Chemokines
2.3.1 General properties
Chemokines are small, secreted proteins that belong to a molecular superfamily that shares
structural similarities: all members possess four conserved cystein residues that form disulfide
bonds that are crucial for tertiary structure. In CC-­‐chemokines like CCL17, the first two cystein
residues are adjacent whereas in CXC-­‐chemokines like CXCL9, another amino acid is situated
between the first two cysteins (39).
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Chemokines can be grouped in inflammatory / inducible and homeostatic / constitutive
mediators based on their expression and function (39). Expression of inflammatory
chemokines is induced in the periphery at sites of inflammation whereas homeostatic
chemokines are constitutively expressed in lymphoid organs. The latter are known for guiding
immune cells to the sites of their destination by establishing a chemokine concentration
gradient, which cells bearing the appropriate receptor can follow. During immune responses,
the expression pattern of chemokine-­‐receptors on a cell and therefore their homing behaviour
change. T cells in their naïve state express CCR7 and CXCR4, whose ligands are expressed in
lymphoid organs and attract naïve T cells to a restricted area in secondary lymphoid organs.
Upon activation, T cells downregulate CCR7, thereby inhibiting further circulation through
secondary lymphoid organs, and upregulate other receptors including CCR2, CCR3, CCR4,
CCR5, CCR6, CCR8, CXCR5 and CXCR3 (40). The ligands for these receptors are expressed in
inflamed peripheral organs, thereby directing activated T cells to sites of inflammation.
Chemokines bind to receptors that belong to the superfamily of seven transmembrane domain
G protein coupled receptors (GPCR). These receptors are associated with cytosolic
heterodimeric G proteins that consist of a Gα, Gβ and Gγ subunit. So far approximately 20 Gα,
6 Gβ and 11 Gγ have been described, indicating the high diversity of GPCR signalling (41). Upon
ligand binding the Gα subunit dissociates from the Gβ/Gγ complex. The signal is transduced
mostly by the Gα subunit but sometimes also through the Gβγ complex. All G proteins engage
multiple signaling pathways with various intracellular intermediataries including ion channels,
transcription factors and metabolic enzymes. Thereby, a complex network is generated in
which signals from GPCRs can be integrated with signals from other receptors.
Chemokines are characterized by a certain degree of redundancy: there can be many ligands
binding to the same receptor and vice versa. One example is CCR5, which binds CCL3, CCL4 and
CCL5, of which CCL3 and CCL5 can additionally bind to CCR1 (41). Another example is CCR4
that has two ligands, CCL17 and CCL22 (42, 43).
2.3.2 The chemokine receptor CCR4 and its ligands
Originally, CCR4 expression was associated with T helper cell type 2 (TH2) responses in allergic
conditions in airways or skin (44,45,46). More recently, its expression has been detected on
Langerhans cells, monocytes, NK cells, NKT cells, platelets and regulatory T cells (47,48,49).
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The best described CCR4 ligand CCL17, also known as thymus-­‐ and activation-­‐regulated
chemokine (TARC), has been identified in mice as one of few gene products whose expression
is highly DC-­‐restricted, with constitutive CCL17 expression in thymus, lymph nodes and lung
but complete absence in splenic DCs, even after systemic application of different TLR ligands
(42,45).
The pathophysiological role of CCL17 has been studied in vivo in different disease models.
CCL17 deficient mice had reduced contact hypersensitivity (45), these results being in line with
studies on patients suffering from atopic dermatitis that showed increased CCL17 levels, which
strongly correlated with disease severity (46). Kawasaki et al. demonstrated that allergic
airway hyper-­‐responsiveness also depended on CCL17 as application of a neutralizing CCL17-­‐
antibody could significantly reduce the response in allergen-­‐treated mice (50). In these
models, disease severity depended on the capacity of CCL17 to recruit TH2 cells to sites of
inflammation, leading to the release of high amounts of cytokines.
A second CCR4-­‐specific ligand has been identified, macrophage-­‐derived chemokine (MDC) or
CCL22 (43) although this chemokine is less well characterized. Despite the fact that both
chemokines bind to CCR4, they have additionally been shown to bind the scavenging non-­‐
signaling decoy receptor D6 (51). Moreover CCL17 has been described to bind to eosinophils in
a CCR4-­‐independent fashion, suggesting the putative existence of a novel unidentified
receptor for CCL17 (52). Stutte et al. (53) described a relation between CCL17 and the
chemokine receptors CCR7 and CXCR4. They observed a migratory defect in CCL17-­‐deficient
but not CCR4-­‐deficient cutaneous DCs in atopic dermatitis and could demonstrate that CCL17
sensitizes DCs for CCR7-­‐ and CXCR4-­‐dependent migration.
2.3.3 Chemokines as regulators of immune responses
The concept of DC licensing indicates that the cross-­‐presenting DC has to physically interact
with both specific CD4+ and CD8+ T cells. Such interactions need to be regulated to ensure an
encounter of rare antigen-­‐specific cells, and chemokines are the molecular agents that fulfill
this purpose.
Under homeostatic conditions, an optimal immune surveillance is mediated by CCR7 and
CXCR5 expression on T and B cells and secretion of the appropriate ligands in T and B cell zones
of secondary lymphoid organs. Lack of CCR7 thus leads to profound morphological alterations
resulting in a dissolved microstructure of secondary lymphoid organs (54). Chemokine
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receptor-­‐ and ligand-­‐expression are regulated in a highly sophisticated fashion: for example,
upregulation of CCR7 on matured DCs ensures the migration of antigen-­‐experienced, mature
DCs along lymphoid vessels towards T cells zones, where endothelial cells express the CCR7
ligand CCL21 (55). On the other hand, all naïve T cells express CCR7, which allows them to
recirculate within secondary lymphoid organs and make contact with CCL19-­‐producing DCs
inside of T cell zones (56).
Castellino et al. described the involvement of a different chemokine receptor in the initiation
of T cell responses. They could show that CD8+ T cells were preferentially attracted towards
mature DCs that had previously been licensed by another T cell (57). This attraction depended
on CCR5 on T cells and happened in an antigen-­‐independent way. Another report by Hugues et
al. confirmed the involvement of CCR5 in T cell help by demonstrating that naïve CD8+ T cells
were preferentially attracted to mature DCs that had previously interacted with antigen-­‐
specific CD8+ T cells (58)
2.4 Aims of this study
Besides classical DC licensing, which is mediated by recognition of peptide antigens through a
CD4+ TH cell, DCs can also be licensed after recognition of lipid antigens by NKT cells. Little is
known about the mechanisms underlying NKT cell-­‐mediated DC licensing except that DCs
mature and upregulate costimulatory molecules. It was my task to clarify the mechanisms
underlying NKT cell mediated cross-­‐priming. As classical licensing is regulated by the
chemokine receptor CCR5, one obvious question was if the same mechanism applies for NKT
cell-­‐mediated DC licensing. The finding that not CCR5 but CCR4 regulates this alternative
licensing pathway was surprising as CCR4 and its two ligands have been linked to memory CD4+
T cell responses, especially of the TH2 type, and to allergic responses of airways and skin. By
contrast, little is known about their role in CD8+ T cell responses in the spleen. This led me to
investigate the role of CCR4 in more detail. Furthermore, I addressed the question why
different licensing events are regulated by distinct chemokines, in order to develop a clearer
picture of the chemokine cross-­‐talk in health and disease.
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3 Materials and Methods
3.1 Materials
3.1.1 Equipment
Equipment Name and company
Autoclave Belimed, CologneBeakers 5, 10, 25, 50, 100, 250, 500 ml (Schott, Mainz)Cell counting chamber Neubauer (Brand, Wertheim)Centrifuges Multifuge 3s-­‐r, Biofuge fresco (Heraeus, Braunsschweig)ELISA reader SpectraMax 250 (Molecular Devices, Sunnyval, USA)Flow cytometers FACS CantoII (BD Biosciences, Heidelberg)Freezers (-­‐20°C) Liebherr, BiberachFreezers (-­‐80°C) Hera freeze (Heraeus, Braunschweig)Freezing container Nalge Nunc Cryo (Nunc, Wiebaden)Heating block ThermoStat plus (Eppendorf, Hamburg)Ice machine Icematic (Scotsman®, Frimont Bettolinc, Pogliano, Italy)Incubators HERAcell (Heraeus, Braunschweig)MACS cell separator QuadroMACS (Miltenyi Biotec, Bergisch-­‐Gladbach)Magnet stirrer IKA® Laboratory Equipment, StaufenMeasuring cylinders 50 ml, 100 ml, 250 ml, 500 ml, 1l (Schott, Mainz)Microscopes IX71 and CKX31 (Olympus, Hamburg)pH-­‐meter pH523 (Wissenschaftlich-­‐Techn. Werkstätten, Weilheim)Pipette-­‐Boy Pipetus (Hirschmann Labortechnik, Eberstadt)
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Pipettes Eppendorf, Hamburg and Gilson, HeidelbergPreparation instruments Labotec, GöttingenRefrigerators (+4°C) Bosch, Stuttgart and Liebherr, BiberachSieves, steel University of Bonn, Department “Feinmechanik”Water bath (37°C) TW8 (Julabo, Seelbach)Workbench, sterile HERAsafe (Heraeus, Hanau)
3.1.2 Software
Software Company
Cell F Olympus, HamburgCorel Draw Corel CorporationFACS Diva V6.1.1 BD Biosciences, HeidelbergFlowjo V8.8.6 Tree star, Inc., USAImage J NIH Bethesda, USAMicrosoft Office 2008 Microsoft, USAPhotoshop CS4 Adobe, USAPrism5 for Macintosh GraphPad Software, USASPF ELISA software Molecular Devices, USA
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3.1.3 Consumables
Consumables Name and company
Cover slides 21x46 mm (Marienfeld, Lauda-­‐Königshofen)Cryo vials VWR International, DarmstadtCyromolds VWR International, DarmstadtELISA plates Microlon, 96-­‐wll, flat-­‐bottom (Greiner bio-­‐one, Solingen)FACS tubes polystyrene, 12/75 mm (Sarstedt, Nümbrecht)Injection needles 27G, 25G, 20G (BD Microlance, Heidelberg)Microtiter plates 96-­‐well, round and flat bottom (Greiner bio-­‐one, Solingen)Parafilm Parafilm “M”®(American National Can TM, Greenwich, USA)Pasteur pipettes 150 mm and 230 mm (Roth, Karlsruhe)Petri dishes 10 cm (Greiner bio-­‐one, Solingen)PD10 column Amersham, UppsalaPipette tips 10 µl, 200 µl, 1000 µl (Greiner bio-­‐one, Solingen)Plastic pipettes 5ml, 10 ml, 25 ml (Sarstedt, Nümbrecht)Polypropylene tubes sterile, 15 ml and 50 ml (Greiner bio-­‐one, Solingen)Reaction tubes 0.5 ml, 1.5 ml, 2 ml (Eppendorf, Hamburg)Sterile filter 0.2 µm (Schleicher & Schuell)Syringes 2, 5, 10, 20 ml BD Discardit™ (BD Bioscience, Heidelberg)Tissue culture plates 12-­‐, 96-­‐well (Sarstedt, Nümbrecht)Transwell inserts 5µm Corning (Labomedic, Bonn)
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3.1.4 Chemicals and reagents
Reagent Company
2-­‐methyl butane Merck, Darmstadtα-­‐galactosylceramide Axxora, Lausen, Switzerlandα-­‐GalDAG Patrick Perlmutter, ClaytonAmmonium chloride (NH4Cl) Merck, Darmstadtβ-­‐mercaptoethanol Sigma Aldrich, MunichBovine serum albumin (BSA) Roth, KarlsruheCarboxyfluorescein succinimidyl ester (CFSE) Molecular Probes, Leiden, NetherlandsCCL17 recombinant mouse RnD Systems, WiesbadenCpG oligodeoxynucleotides TIB MolBiol, BerlinCollagenase A Roche, MannheimDisodium hydrogen phosphate (Na2HPO4) Merck, DarmstadtDMEMmedium Sigma Aldrich, MünchenEthanol, absolute Merck, DarmstadtEthylene diamine tetraacetic acid (EDTA) Merck, DarmstadtFar Red fluorochrome Molecular Probes, Leiden,NetherlandsFetal calf serum (FCS) PAA, CölbeGlogi Plug/Stop BD Biosciences, HeidelbergGSL1´ provided by Paul Savage, Provoh USAHoechst 33342 Molecular Probes, Leiden,NetherlandsHydrogen peroxide (H2O2) Merck, DarmstadtIFNg, ELISA duoset BD Biosciences, Heidelberg
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IFNγ, recombinant mouse Biolegend, San Diego, USAIsoglobotrihexosylceramide (iGb3) Axxora, Lausen, SwitzerlandIL-­‐2, -­‐4, -­‐6, -­‐12, -­‐13 recombinant mouse Biolegend, San Diego, USAL-­‐glutamine (200 mM) PAA, CölbeLiquid nitrogen Linde, WiesbadenOCH Axxora, Lausen Switzerland
o-­‐Phenylenediamine dihydrochloride (OPD) Sigma Aldrich, MünchenOvalbumin (OVA), grade V Sigma Aldrich, MünchenParafomaldehyde Fluca, BuchsPenicillin/Streptomycin PAA, CölbePhosphate buffered saline (PBS) Biochrom, BerlinPotassium bicarbonate (KHCO3) Merck, DarmstadtRPMI 1640 medium Invitrogen, DarmstadtSaponin Sigma Aldrich, MünchenSIINFEKL peptide (OVA254-­‐267, S8L) Sigma Aldrich, MünchenSodium bicarbonate (Na2HCO3) Sigma Aldrich, MünchenSodium hydroxide (NaOH) Merck, DarmstadtSulfuric acid (H2SO4) Merck, DarmstadtTissue-­‐Tel® OCT Sakura, NetherlandsTrypane blue (0.4 %) Lonza, KölnTween20 Roth, Karlsruhe
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3.1.5 Buffers, media and solutions
5 mM β-­mercaptoethanol178 μl of 14.3 M β-­‐mercaptoethanol was added to 500 ml PBS and kept under sterileconditions at 4°C.
DC and T cell culture mediumRPMI 1640 medium was supplemented with 10% (v/v) FCS, 1% (v/v) L-­‐glutamine, 1%(v/v) penicillin/streptomycin, 1% (v/v) sodium pyruvate, and 1% (v/v) of 14.3 M β-­‐mercaptoethanol. Kept under sterile conditions at 4°C.
FCS (fetal calf serum)FCS was heat-­‐inactivated at 56°C for 30 min and stored à 50 ml aliquots at -­‐20°C.
PBS (phosphate buffered saline)1xPBS was adjusted to pH 7.4, aliquoted à 500 ml, autoclaved and stored at 4°C.
Erythrocyte lysis buffer16.58 g NH4Cl, 2 g KHCO3, 74.4 mg Na2EDTA was dissolved in 2000 ml ultra-­‐pure waterand the pH was adjusted to 7.2 -­‐ 7.4. Stored under sterile conditions at 4°C.
FACS buffer1x PBS containing 0,1% (v/v) BSA and 0.1% (v/v) NaN3. Stored at 4°C.
MACS buffer1x PBS containing 0,1% (v/v) BSA and 2mM EDTA. Stored under sterile conditions at 4°C.
Saponin bufferFACS buffer supplemented with 0.5% (w/v) saponin, prepared freshly.
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ELISA coating buffer0.1 M NaHCO3 in ultra-­‐pure water, pH 8.2, autoclaved and stored at 4°C.
ELISA blocking buffer1% BSA (w/v) in 1xPBS, stored at 4°C.
OPD substrate buffer15.6 g NaH2PO4 x 2 H2O and 14.7 g Na3C6H5O7 x 2 H2O were dissolved in 500 ml ultrapurewater and the pH was adjusted to 5.0. The buffer was stored at room temperature.
1M H2SO4 OPD stopping solution26.5 ml 96% H2SO4 was added to 500 ml ultra-­‐pure water and kept at room temperature.
ELISA washing buffer1x PBS containing 0.01% (v/v) Tween20
4% (w/v) PFA solution8 g PFA was dissolved in 200 ml 1xPBS by gradual heating. The pH was adjusted to 7.4 andaliquots were stored at -­‐20°C.
3.1.6 Antibodies
Antibodies used in cytokine ELISAAll antibodies used for cytokine ELISAs were purchased from eBioscience or BDPharmingen. Matching antibody pairs included a primary unlabeled capture antibody anda biotinylated detection antibody. Each antibody was applied in previously titratedamounts. Clones XMG1.2 (IFNγ capture antibody) and RA-­‐6A2 (IFNγ detection antibody)were used.
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Antibodies coupled to magnetic beads (MACS® Beads)Murine anti-­‐CD8a, anti-­‐CD4, anti-­‐CD19 and anti-­‐CD11c antibodies conjugated to magneticbeads (MACS® Beads) were obtained from Miltenyi Biotech, Bergisch Gladbach.
Antibodies for immunohistology and flow cytometric analysisThe following antibodies were purchased from eBioscience, BD Biosciences or MolecularProbes (if not otherwise stated) for flow cytometric analysis of murine moleculesexpressed at the cell surface or intracellularly. All antibodies were employed at previouslydetermined concentrations, and mostly diluted 1:200 in FACS buffer.
Antigen Clone Conjugate ApplicationCD1d 3C11 Biotin Flow cytometryCD3ε 145-­‐2C1117A2 APCAPC Cell sortingFlow cytometryCD4 GK1.5RM 4-­‐5 unconjugatedAlexa Fluor 405 In vivo depletionFlow cytometryCD8α 53-­‐6.753-­‐6.753-­‐6.7
APCPEPerCPCy5.5
Flow cytometryFlow cytometryFlow cytometryCD11c N418N418 APCFITC Flow cytometryFlow cytometryCD54R (B220) RA3-­‐6B2 PE ImmunohistochemistryCD80 MCA1586F APC Flow cytometryCD86 GL-­‐1 APC Flow cytometryH2-­‐Kb (MHC class I) AF6-­‐88.5.5.3 PE Flow cytometryI-­‐Ab (MHC class II) M5/114.15.2 PE Flow cytometryNK1.1 PK136PK136 PECy7APC Cell sorting,Flow cytometryStreptavidin PEAlexa405 Flow cytometryFlow cytometry
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3.1.7 Mouse strainsC57BL/6(N) wild type strains (H-­‐2Kb) were purchased from Charles River, Harlan, orJanvier, France. Mice were bred under specific pathogen-­‐free conditions and in accordanceto institutional animal guidelines in the animal facility (HET, House of ExperimentalTherapy) of the University of Bonn. Mice were used at 8-­‐12 weeks of age. Following knock-­‐out (ko) or transgenic animals backcrossed on C57BL/6 were used:
Mouse strain Description
Bm1 This mouse strain has a point mutation in their MHC class I molecule thatprevents presentation of the OVA-­‐peptide SIIFEKL to CD8+ T cells.CCL17-­‐eGFP This mouse strain expresses an eGFP knock-­‐in construct under the controlof the CCL17 promotor and can therefore be used as CCL17 reporter mice.Heterozygous animals can still produce CCL17, albeit at reduced amounts.Homozygous CCL17-­‐eGFP mice can also be employed as CCL17 reportersbut do not produce the chemokine, permitting their use as CCL17 ko mice.CCR4ko This mouse strain is deficient for the chemokine receptor CCR4.CCR5ko This mouse strain is deficient for the chemokine receptor CCR5.CCR4ko OT-­‐I This OT-­‐I mouse strain lacks the CCR4 locus.MHCIIko This mouse strain is deficient in the H2-­‐Ab1 locus and does not have anyfunctional CD4+ T cells due to developmental defects.CD1dko This mouse strain is deficient in the CD1d locus and thus lacks NKT cells dueto developmental defects.CD8ko This mouse strain lacks CD8+ T cells due to developmental defects.IL-­‐4ko This mouse strain is deficient for the cytokine IL-­‐4.OT-­‐I RAG This mouse strain bears a transgenic T cell receptor that recognizes the OVA257-­‐264 peptide (SIINFEKL) in H-­‐2Kb molecules. The line is backcrossed on
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a RAG-­‐deficient background, leading to a defect in somatic recombination ofTCR segments. Hence, this mouse contains T cells that almost exclusivelyhave antigen specificity for the SIINFEKL peptide.
3.2 Methods
3.2.1 Experimental treatment of miceCells and reagents were adjusted in PBS for experimental injection. Intravenous (i.v.) andintraperitoneal (i.p.) injections were performed with a volume of 200 µl, subcutaneousinjections (s.c.) in the tail basis in a volume of 100 µl.Soluble ovalbumin (OVA) was injected intravenously (10 µg per gram body weight),accompanied when appropriate by 0.2 µg (1 nmol) of αGalCer, 1 nmol of iGb3, aGalDAG,OCH, GSL1´ or 20 µg of CpG oligodeoxynucleotides. αGalDAG was a gift from PatrickPerlmutter (Monash University, Clayton, Australia) and prepared by an adaptation of apubished method (59). GSL1´was a gift from Paul Savage (Department of Chemistry andBiochemistry, Brigham Young University, Provo, Utah, USA) and was synthesized aspublished (60).
3.2.2 Isolation and transfer of primary murine cells
3.2.2.1 Isolation of splenic dendritic cellsSpleens were removed and digested by perfusion with 0,4 mg of collagenase and DNAseper ml of PBS. After incubation for 20 minutes at 37°C, spleens were homogenized througha metal cell strainer and resuspended in cell culture medium or PBS + 0,1% BSA. Cellswere centrifuged for 5 min at 1200 rpm and the supernatant was discarded. For DCpurification, the cell pellet was resuspended in 600 μl of MACS buffer containing 20 μl ofanti-­‐CD11c conjugated magnetic microbeads per spleen and the sample was incubated for15 min at 4°C. Afterwards, MACS buffer was added and cells were centrifuged for 5 min at1200 rpm in order to remove unbound magnetic beads. Cells were then resuspended in 3ml of MACS buffer and purified via magnetic columns, which had been equilibrated with 3ml of MACS buffer before. Elusion of cells from the columns was performed with 4 ml ofMACS buffer.
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Depending on the experiment, DCs were left untreated or pulsed with SIINFEKL peptide ata concentration of 20 µg per ml for 20 minutes at 37°C.
3.2.2.2 Isolation of CD8+ T cellsFor the isolation of CD8+ T cells from spleen and lymph nodes, the respective lymphoidorgans were extracted and homogenized through a metal cell strainer. After centrifugationfor 5 min at 1200 rpm, CD8+ T cells were isolated by magnetic cell sorting as describedabove (3.2.2.1) sorting using anti-­‐CD8 conjugated magnetic microbeads.
3.2.2.3 Isolation of splenic NKT cellsA single cell suspension from spleens was prepared by using a metal cell strainer. CD19positive cells were excluded from suspensions by anti-­‐CD19 conjugated magneticmicrobeads as described above (3.2.2.1) before staining NKT cells with anti-­‐CD3 and anti-­‐NK1.1 antibodies for flow cytometry based cell sorting, isolating CD3+ NK1.1+ cells.
3.2.2.4 Cell countingFor determination of cell numbers, cell suspensions were diluted in Trypan Blue solution(10 µl in 190 µl), and 10 µl were applied to a Neubauer counting chamber. Four largesquares of the chamber were counted, with only viable (unstained) cells being considered.The total cell number was calculated by using the following formula:
(Counted cell number)/4 x 20 (dilution factor) x 10,000 (chamber factor)
3.2.3 In vitro cross-­priming assay
3.2.3.1 In vitro assayDCs and CD8+ T cells were isolated from spleen as described above (see 3.2.2.1 and3.2.2.2). 1,5 x 105 T cells were labeled with CFSE (see 3.2.7) and cocultured with DCs at aratio of 3:1 or anti-­‐CD3 plus anti-­‐CD28 beads in 96-­‐well plates. Before coculture, DCs werepulsed with SIINFEKL peptide at a concentration of 20 µg per ml for 20 minutes at 37°C.Cells were cultured in a total volume of 200 µl at 37°C, with a relative humidity of 90% anda CO2 content of 5%. After 24 h, 100 µl of supernatant were removed for ELISA analysis
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(see 3.2.4). After three days of coculture, activation of CD8+ T cells was assessed by CFSEdilution (see 3.2.7).
3.2.3.2 Detection of IFNγ by enzyme-­linked immunosorbent assay (ELISA)Cytokine production was measured by using an IFNγ-­‐specific sandwich ELISA. Therefore,a 96-­‐well ELISA microtiter plate was coated with 50 μl of the primary unconjugatedcapturing antibody per well (1:180 in coating buffer) overnight at 4°C. Plates were washedtwice with 0.05% Tween20 in PBS before free binding sites were blocked with 100 μl of1% BSA/PBS per well for one hour at room temperature. Afterwards, 50 µl of each samplewere applied to the plate. In addition, a cytokine standard was prepared in order to allowquantification of the cytokine concentration after measurement. Usually, the standard wasdetermined at least in duplicate and a two-­‐fold dilution series was used, starting at aconcentration of 8 ng per ml. After incubation at 4°C over night, plates were washed threetimes with 0.05% Tween20 in PBS and 50 µl of a biotinylated goat anti-­‐mouse IFNγantibody (1:180 in coating buffer) were added per well. After two hours of incubation atroom temperature, plates were washed extensively and then incubated for at least 45minutes with 50 µl per well of streptavidin-­‐couples horseradish peroxidase (1:5000 inPBS), followed by three washing steps. Afterwards, OPD buffer supplemented with OPD (1mg per ml) and H2O2 (1µl per ml) was added at a volume of 100 µl per well and thereaction was stopped with a 1M solution of H2SO4 as soon as colour development hadreached saturation in one of the samples. Finally, peroxidase-­‐mediated colour intensitywas detected using an ELISA plate reader (wave length: 490 nm).
3.2.4 CFSE proliferation assay of CD8+ T cellsFor fluorochrome labeling of CD8+ T cells, OT-­‐I cells or endogenous polyclonal CD8+ T cellswere isolated from mice as described (see 3.2.2.2). Single-­‐cell suspensions were thentreated with erythrolysis buffer for 5 minutes and isolated via MACS purification. For Tcell labeling, 106 cells per ml were taken up in PBS and 5 µM (for in vivo use) or 1 µM (for
in vitro use) of CFSE were added for 10 minutes at 37°C. Afterwards, the staining reactionwas stopped by adding excess PBS and cells were washed twice with PBS and centrifugedfor 5 minutes at 1200 rpm. For transfer into 96-­‐well plates or animals, cell number wasadjusted in PBS appropriately.
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3.2.5 In vivo cytotoxicity assay
In vivo cytotoxicity assays were performed as previously described (61). Briefly, spleensuspensions were pulsed for 15 min at 37 °C with OVA peptide (SIINFEKL; 2 µg/ml) andlabeled with 1 µM CFSE (CFSEhi cells) or were not pulsed with peptide and were labeledwith 0.1 µM CFSE (CFSElo cells). Both target celltypes (0,5x107 each) were injectedintravenously. After 4 h, the survival of target cells in the spleen was analyzed by flowcytometry. Specific lysis was calculated with the following formula: % specific cytotoxicity= 100 − ((CFSEhi / CFSElo) primed / (CFSEhi / CFSElo) control)x100.
3.2.6 Flow cytometry
3.2.6.1 Staining of surface moleculesTo assess the expression of surface markers, respective organs were harvested from mice,digested with collagenase and DNAse when appropriate (if DCs were to be analyzed, see3.2.2.1), and homogenized through a metal cell strainer. After centrifugation for 5 minutesat 1200 rpm, erythrocyte lysis was performed by incubation of erythrolysis buffer for 5minutes. The reaction was stopped by adding excess PBS and subsequent centrifugationfor 5 minutes at 1200 rpm. Subsequently, 50 µl of blocking serum was added and sampleswere incubated for 15 minutes on ice in order to fill unspecific binding sites and Fcreceptors. After further centrifugation, staining was performed for 20 minutes on ice.Antibodies listed in Table 3.1 were diluted in FACS buffer (1:200 if not indicatedotherwise). The staining reaction was stopped by adding excess FACS buffer andcentrifugation for 5 minutes at 1200 rpm. Finally, the cell pellet was taken up in FACSbuffer and analyzed by flow cytometry.
3.2.6.2 Intracellular cytokine stainingIntracellular staining for IFNγ was performed in order to assess T cell activation in vivo.Three days after immunization, T cells were isolated from spleen as described above (see3.2.2.2), taken up in cell culture medium. Afterwards, SIINFEKL peptide was added at aconcentration of 20 µg per ml in order to restimulate CD8+ T cells after isolation.Moreover, GolgiPlug reagent was added at a concentration of 1 µl per ml to preventsecretion of newly synthesized cytokines, but rather lead to intracellular cytokine storage.The mixture was incubated for four hours at 37°C. The cells were then washed with PBSand stained with a PE-­‐coupled anti-­‐mouse CD8 antibody (1:200 in FACS buffer),supplemented with blocking serum (1:200) to prevent unspecific binding. After 20
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minutes, the suspension was centrifuged for 5 minutes at 1200 rpm and subsequentlyexposed to 100 µl of fixation reagent containing paraformaldehyde (2% in PBS) for 15minutes at room temperature. Importantly, exposure to light was avoided as much aspossible. Cells were then washed again and taken up in saponin buffer (0.5% of saponin inFACS buffer) and cell membranes were made permeable for 20 minutes at roomtemperature, followed by centrifugation. Staining was performed with an APC-­‐coupledanti-­‐mouse IFNγ antibody that was diluted 1:200 in saponin buffer and also supplementedwith blocking serum. The reaction took place at room temperature for 30 minutes.Afterwards, cells were washed twice in saponin buffer and one more time with FACSbuffer before being taken up in 300 µl of FACS buffer for flow cytometric analysis.
3.2.6.3 S8L/H-­2Kb-­specific tetramer stainingThe tetramer staining reagent was used to determine the amount of T cells specific forSIINFEKL peptide and hence their activation after immunization with soluble ovalbumineor the transfer of SIINFEKL-­‐presenting DCs. To this end, splenic CD8+ T cells were isolatedas described (see 3.2.2.2) and resuspended in a staining solution that contained APC-­‐coupled S8L/H-­‐2Kb-­‐specific tetramers and blocking serum in FACS buffer. After anincubation time of 20 minutes at room temperature, a PE-­‐coupled anti-­‐mouse CD8antibody was added (1:200 in FACS buffer) and further incubation was performed on icefor another 20 minutes. Two washing steps with FACS buffer and flow cytometric analysisthen followed the staining.
3.2.7 Generation of mixed bone marrow chimerasBone marrow cells were obtained from femurs of donor mice. Mice were irradiated with 9Gy from a 137Cs source and then were injected intravenously with a 1:1 mixture of a totalof 1x107 bone marrow cells. The ratio of bone marrow types used was always 50%+/-­‐10%of each type at 8 weeks after transplantation.
3.2.8 Immunohistochemistry
3.2.8.1 Isolation and labeling of CD8+ T cellsCCR4-­‐deficient or CCR4-­‐sufficient OT-­‐I T cells or endogenous CD8+ T cells were isolatedfrom spleens as described above (see 3.2.2.2). After magnetic separation, T cells were
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resuspended in 5 ml of PBS in a 15 ml tube and 2.5 µl of FarRed staining solution (DDAO-­‐SE, 7-­‐hydroxy-­‐9H-­‐(1,3-­‐dichloro-­‐9,9-­‐dimethylacridin-­‐2-­‐one)-­‐succinimidyl ester) wereadded into the lid of the tube, which was carefully inverted thereafter. Due to potentialcytotoxicity of the reagent, cells were stained for no longer than 20 minutes at 37°C. Thereaction was stopped by adding 7 ml of ice-­‐cold PBS and followd by centrifugation at 1200rpm for 6 minutes. After resuspension in PBS, the cell number was adjusted to 12.5 ∙ 106cells per ml of PBS. Finally, 200 µl (2.5 ∙ 106 cells) were injected intravenously. 16 hoursafter adoptive transfer, antigen and adjuvant were administered i.v. where appropriate.
3.2.8.2 Preparation of cryosections10 hours after immunization, spleens were isolated, briefly rinsed in ice-­‐cold PBS anddirectly embedded in Tissue-­‐Tek®. Afterwards, tissue blocks cooled down to -­‐20°C andcould be stored for up to a week or longer if transferred to -­‐80°C. Cryosections of a widthof 5 µm were prepared from frozen tissue blocks by using a microtome/cryostat at aworking temperature of -­‐18°C. In order to avoid staining of the same cells in differentsections, at least two sections between individual slides were discarded.
3.2.8.3 Immunofluorescence stainingSections were fixed with iced acetone for 10 minutes at 4°C and afterwards air-­‐dried forsome minutes. Fixation time did not exceed 10 minutes, in order to avoid a loss of tissueintegrity. Blocking solution (1% BSA in PBS) was applied for one hour at roomtemperature, stained with anti-­‐B220-­‐PE antibody (diluted 1:200 in blocking solution) forone hour and then washed twice with PBS. Finally, sections were covered with mountingmedium and cover slides, and could be stored for up to a week if not exposed to light.
3.2.8.4 Quantification of cell numbersStained sections were viewed and images were captured with a fluorescence microscope.T cell numbers were counted (utilizing the “Touch count” mode) in T cell areas(determined as “closed polygons”) with Cell F software (Olympus). In addition, as distinctlabels for DCs and CTLs were used, intercellular contacts were enumerated. Both cell typeswere considered to be in direct contact when fluorescence signals partially overlapped orwere directly adjacent to one another.
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3.2.9 In vitro analysis of CD8+ T cell recruitment by DCsCD8+ T cells and DCs obtained from the spleen were labeled with different fluorochromesand mixed at a ratio of 4:1 in RPMI medium containing 2% (vol/vol) FCS and then wereplaced on plastic channel slides (µ-­‐slide; Ibidi) coated with fibronectin (Harbour Bio-­‐Products). Time-­‐lapse series were recorded with a fully automated inverted OlympusFluoview 1000 confocal microscope equipped with motorized xyz stage (Märzhäuser) anda climate chamber (37 °C and 5% CO2 with humidity). Up to eight samples were analyzedsimultaneously with the multipoint function of the microscope, which allowed use of thesame conditions for all probes. Cell motility and cell-­‐cell interactions were monitored overa period of 2 h by capture of fluorescence and differential interference contrast imagesevery 2 min with a 0.75 Plan S Apo 20x objective (Olympus). In each experiment, 100–300motile CD8+ T cells were tracked with the Manual Tracking plug-­‐in of ImageJ software(National Institutes of Health). The directionality of migrating CD8+ T cells before physicalcontact with DCs, as well as the duration of cell-­‐cell interactions, was calculated with theChemotaxis and Migration Tool plug-­‐in (Ibidi) of ImageJ software. For analysis ofdirectionality, the ratio of euclidean to accumulated distance of individual cell tracks wascalculated (sample of analysis, Fig. 3.2.9.1). CD8+ T cell directionality and CD8+ T cell-­‐DCcontact in high resolution was also analyzed as a time series with a 0.9 ultraviolet-­‐transmitting Plan Apo 40x objective (Olympus).
3.2.10 Transwell cell-­migration assaySplenocytes (1x106) from aGalCer-­‐injected wild-­‐type mice were loaded into the topchamber of Transwell inserts (pore size, 5 µm; Costar). Bottom wells were filled withRPMI medium containing 2% (vol/vol) FCS with or without CCL17 (R&D Systems). Cells inthe lower chambers were collected after 6 h at 37 °C and transmigrated CD8+ T cells werecounted by flow cytometry with antibody staining and the addition of constant numbers ofCaliBRITE beads (BD Biosciences).
3.2.11 Real-­time reverse-­transcription PCRRNA was isolated with the RNeasy Micro Kit (Qiagen), then cDNA was synthesized withrandom hexamer primers. An ABI Prism 7000 Sequence Detection system (AppliedBiosystems) was used for RT-­‐PCR with the following settings: 40 cycles of 15 s ofdenaturation at 95 °C, and 1 min of primer annealing and elongation at 60 °C as described(62). RT-­‐PCR was done with 1.5 µl cDNA plus 2.5 µl (0.9 µM) specific primers and 12.5 µl
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of 2°— Platinum SYBR Green qPCR SuperMix (Invitrogen), and the following primers:mCCL17 1 (5-­‐TGGTATAAGACCTCAGTGGAGTGTTC-­‐3´) and mCCL17 2 (5-­‐GCTTGCCCTGGACAGTCAGA-­‐3); and mCCL22 1 (5-­‐GAGTTCTTCTGGACCTCAAATCC-­‐3) andmCCL22 2 (5-­‐TCTCGGTTCTTGACGGTTATCA-­‐3); mCCL3 1 (TCTGTCACCTGCTCAACATCAT)and mCCL3 2 (CGGGGTGTCAGCTCCATA); mCCL4 1 (AAACCTAACCCCGAGCAACA) andmCCL4 2 (CCATTGGTGCTGAGAACCCT); mCCL5 1 (GCTGCTTTGCCTACCTCTCC) andmCCL5 2 (TCGAGTGACAAACACGACTGC).All samples were run in duplicates and results were normalized to those of 18S rRNA orGAPDH.
3.2.12 Statistical analysisComparisons were made with the Mann-­‐Whitney or Kruskal-­‐Wallis test and Dunn’s post-­‐test, Student´s t-­‐test, or one-­‐way ANOVA and Dunnets, Bonferroni or Tukey post-­‐test usingPrism 5 software (Graphpad Software).
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4 Results
4.1 NKT cell-­mediated DC licensing
4.1.1 Cognate NKT cell-­mediated licensing is independent of CD4+ help
Naïve CD8+ T cells need several stimulatory signals provided by a cross-­‐presenting DC for their
proper activation. DCs on the other hand only gain their full cross-­‐priming capacity after they
have successfully presented antigen to a CD4+ TH cell and have received activating signals in
return. This process has been termed DC licensing (21). In addition to classical licensing by
CD4+ TH cells, NKT cells have also been demonstrated to be able to mature DCs that present
glycolipid antigens like αGalCer on CD1d (26-­‐28). In the present study, the stimulatory effect of
NKT cells on cross-­‐priming was confirmed in our model by co-­‐injecting the NKT cell ligand
αGalCer with the cross-­‐presented antigen OVA (Fig. 4.1-­‐1a). The positive effect of αGalCer is
mediated by NKT cells as CD1d-­‐/-­‐ mice that lack NKT cells showed no increased T cell response
(Fig. 4.1-­‐1b). Importantly, the boosting effect is independent of CD4+ T cell help, as MHCII-­‐/-­‐
mice that lack classical MHC-­‐II-­‐restricted CD4+ T cells, showed a CD8+ T cell response similar to
wild-­‐type mice, demonstrating that classical and NKT cell mediated DC stimulation represent
two distinct pathways (Fig. 4.1-­‐1b). To investigate whether the same DC that presents αGalCer
and is thus licensed by an NKT cell, has to cross-­‐present OVA to a CD8+ T cell for efficient cross-­‐
priming, mixed bone marrow-­‐chimeras were generated. As recipients, bm1 mice were used
that have a point mutation in their MHC-­‐I molecule and hence cannot present OVA-­‐peptides to
CD8+ T cells. These mice were irradiated and reconstituted with a 1:1 mixture of bone marrow
from CD1d-­‐/-­‐ and bm1 mice, generating chimeras that possess DCs that can only either
present to CD8+ T cells via MHC-­‐I or to NKT cells via CD1d (Fig. 4.1-­‐1c cartoon). In these mixed
bone marrow chimeras, αGalCer did not enhance proliferation of adoptively transferred OVA-­‐
specific CD8+ T cells from OT-­‐I transgenic mice, in contrast to the control group that was
reconstituted with a 1:1 mixture of wild-­‐type and bm1 bone marrow and thus has DCs that
could present to both cell types simultaneously (Fig. 4.1-­‐1c). These results demonstrate that
NKT cells can license DCs independent of CD4+ T cell help.
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Fig. 4.1-­‐1 Cognate NKT cell-­‐mediated DC licensing. OVA-­‐specific cytotoxicity in the spleen on day 5 after
priming wild-­‐type (wt), MHCII-­‐/-­‐ or CD1d-­‐/-­‐ mice with soluble OVA with or without αGalCer (α-­‐GC) (a,b).
Flow cytometric analysis of OT-­‐I cells among splenic CD8+ T cells from bm1 mice reconstituted with 50%
bm1 bone marrow and 50% wild-­‐type or CD1d-­‐/-­‐ bone marrow 8 weeks before, analyzed 3 days after
adoptive transfer of 1x106 OT-­‐I cells and priming with OVA with or without αGalCer. Cartoon depicts to
which cell types DCs can present antigen in CD1d-­‐/-­‐ / bm1 chimeras (c). Data are representative of two
individual experiments (mean and s.d. of three to four mice per group). *** P < 0.001 (Student´s t-­‐test
(a), one-­‐way ANOVA + Dunnets post test (b), one-­‐way ANOVA + Bonferroni multiple comparison post
test (c)).
4.1.2 NKT cell mediated cross-­priming is regulated by CCR4
Classical licensing is regulated by CCR5 and its ligands CCL3, CCL4 and CCL5, which are
produced by DC and CD4+ T cells upon successful antigen-­‐presentation under inflammatory
conditions (57). To investigate whether NKT cell mediated DC licensing is regulated by these
same chemokines, CCR5-­‐deficient mice were challenged with OVA and αGalCer. However,
CCR5-­‐deficient mice gave the same cytotoxic T cell response as wild-­‐type mice (Fig. 4.1-­‐2a).
Surprisingly, cross-­‐priming was severely attenuated in CCL17-­‐deficient and CCR4-­‐deficient mice
(Fig. 4.1-­‐2a,b), although this chemokine receptor has so far been associated with CD4+ TH cell
responses in allergy and hypersensitivity rather than with naïve CD8+ T cell priming. The
reduced cross-­‐priming was not due to intrinsic CD8+ T cell activation-­‐defects in the knockout
animals as polyclonal CD8+ T cells from these mice had the same response as wild-­‐type CD8+ T
cells to stimulation with anti-­‐CD3/anti-­‐CD28 beads (Fig. 4.1-­‐2c). Thus, classical and alternative
NKT cell mediated cross-­‐priming are regulated by separate chemokines.
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Fig. 4.1-­‐2 NKT cell mediated cross-­‐priming is regulated by CCR4 instead of CCR5. OVA-­‐specific
cytotoxicity in the spleen on day 5 after priming wild-­‐type (wt), CCR5-­‐/-­‐, CCR4/-­‐ or CCL17-­‐/-­‐ mice with
soluble OVA with or without αGalCer (a, b). Division indices of endogenous CD8+ T cells of wild-­‐type
(wt), CCL17-­‐deficient (CCL17-­‐/-­‐) or CCR4-­‐deficient (CCR4-­‐/-­‐) mice, labeled with the cytosolic dye CFSE
and left untreated or stimulated with anti-­‐CD3 plus anti-­‐CD28 for 2 days (c). Data are representative of
three experiments (mean and s.d. of three to four mice per group). *** P < 0.001 (one-­‐way ANOVA +
Dunnets post test (a), one-­‐way ANOVA + Bonferroni multiple comparison post test (b, c)).
4.2 Activated NKT cells induce CCL17 expression in splenic DCs
4.2.1 Characterization of CCL17-­producing cells in the spleen
The finding that CCL17 regulates NKT cell-­‐mediated cross-­‐priming was surprising as this
chemokine had been described to be absent from the spleen even after systemic challenge
with various TLR-­‐ligands (45). To investigate CCL17 induction after αGalCer treatment,
heterozygous (CCL17+/-­‐) and homozygous (CCL17-­‐/-­‐) CCL17-­‐eGFP knock-­‐in mice were used
that express GFP under the CCL17 promoter (45). These CCL17-­‐reporter mice were challenged
with αGalCer and spleen sections were analyzed for CCL17 expression 20 h later by
immunohistochemistry. B220-­‐staining enabled discrimination of B cell zones from T cell zones.
Upon analysis, the sections demonstrated strong GFP signal in splenic T cell zones of αGalCer-­‐
treated mice (Fig. 4.2-­‐1a). To further investigate which cells produce CCL17, the phenotype of
CCL17-­‐expressing cells was determined by flow cytometry and it could be observed that CCL17
expression is highly DC-­‐restricted as previously described (45), with mainly CD8+ (16,4%) but
also some CD8-­‐ DC (6,4%) expressing this chemokine (Fig. 4.2-­‐1b). Notably, other NKT cell
ligands were also able to induce CCL17-­‐eGFP expression in splenic DCs in the following order of
potency: aGalCer > OCH > iGb3 > aGalDAG > GSL1´ (Fig. 4.1-­‐2c). To investigate whether the
same DC that interacts with both NKT and CD8+ T cells (Fig. 4.1-­‐1b) also needs to produce
CCL17 for efficient cross-­‐priming, mixed bone marrow chimeras were created that received
bm1 and CCL17-­‐deficient bone marrow in a 1:1 ratio (Fig. 4.2-­‐1d cartoon). In these mice,
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αGalCer-­‐treatment failed to enhance cross-­‐priming of adoptively transferred OT-­‐I cells,
whereas it did enhance the CD8+ T cell response in control chimeras that received a 1:1
mixture of wild-­‐type and bm1 bone marrow. These control chimeras have DCs that can present
to both NKT and CD8+ T cells and can also produce CCL17 (Fig. 4.2-­‐1d). These results indicate
that CCL17 is rapidly induced by DCs after NKT cell activation, and is only able to enhance
cross-­‐priming when it is produced by the cross-­‐presenting DC.
Fig. 4.2-­‐1 CCL17 induction in splenic DCs. Immunofluorescence staining of B cell zones (blue: B220) in
heterozygous CCL17-­‐eGFP reporter mice (CCL17+/-­‐) or CCL17-­‐deficient mice (CCL17-­‐/-­‐) after injection of
αGalCer (α-­‐GC); scale bars 200µm (a). Flow cytometry of spleen cells from CCL17-­‐eGFP reporter mice 5
h after injection of vehicle or αGalCer (α-­‐GC), with gating of CD11c+ cells (red box left) followed by
analysis of the expression of CD8 and CCL17 (red boxes right) (b). Flow cytometry of spleen cells from
CCL17-­‐eGFP reporter mice 20 h after injection of vehicle, αGalCer, OCH, iGb3, GalDAG and GSL1´ (c).
Flow cytometric analysis of the proportion of OT-­‐I cells in splenic CD8+ cells of bm1 mice reconstituted
with 50% bm1 bone marrow and 50% CCL17-­‐deficient (CCl17-­‐/-­‐ / bm1) or wild-­‐type bone marrow (wt /
bm1) 8 weeks before, analyzed on day 3 after adoptive transfer of 1x106 OT-­‐I cells and priming with OVA
plus αGalCer. Cartoon depicts the abilities of DCs to present antigen and produce CCL17 in CCL17-­‐/-­‐ /
bm1 chimeras (d). Data are representative of two experiments (mean and s.d. of three to four mice per
group in each). *** P < 0.001 (one-­‐way ANOVA + Bonferroni multiple comparison post test (d)).
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4.2.2 Mechanism of CCL17 induction by NKT cells
As CCL17 production is induced in an NKT cell dependent fashion within three hours of NKT cell
ligand injection (data from Veronika Lukacs-­‐Kornek, not shown), I hypothesized that the rapid
cytokine production by activated NKT cells might induce CCL17 production in DCs. NKT cells are
known to produce high levels of IL-­‐4, IL-­‐13, IFNγ and TNFα and upregulate CD40L. The
production of IL-­‐4, IFNγ and TNFα by NKT cells 5 h after injection of αGalCer was confirmed by
using a fluorescent bead immunoassay (Bender MedSystems) that allows detection of IL-­‐1α, IL-­‐
2, IL-­‐4, IL-­‐5, IL-­‐6, IL-­‐10, IL-­‐17, IFNγ and TNFα (Fig. 4.2-­‐2a). Subsequently, the influence of these
factors on CCL17 production was tested by culturing DCs that had been obtained from CCL17-­‐
eGFP-­‐reporter mice, with different concentrations and combinations of IL-­‐4, IL-­‐13, IFNγ, TNFα
and a stimulatory anti-­‐CD40 antibody. Flow cytometric analysis revealed that already low
concentrations of IL-­‐4 induced CCL17 production in around 20% of DCs after 15 h of co-­‐culture
(Fig. 4.2-­‐2b). IL-­‐13 also induced some CCL17 but only at higher concentrations and not to the
same degree as IL-­‐4 (Fig. 4.2-­‐2b). In comparison IFNγ did not induce CCL17, but inhibited its
production induced by IL-­‐4 stimulation (Fig. 4.2-­‐2b,c). TNFα alone slightly increased CCL17
expression but to a very low degree and the biological relevance of this effect seems doubtful.
However, TNFα did increase the percentage of CCL17-­‐producing DCs induced by NKT cell-­‐
derived IL-­‐4 or IL-­‐13 (Fig. 4.2-­‐2b,c). Treatment with anti-­‐CD40 did not result in CCL17
expression, and it could not significantly improve IL-­‐13 and TNFα-­‐induced CCL17 production
(Fig. 4.2-­‐2b,c). In summary, CCL17 production can be induced by IL-­‐4 and to some degree by IL-­‐
13, which can be further upregulated by the additional presence of TNFα (Fig. 4.2-­‐2d).
Nevertheless it seems likely that different cytokines can act redundantly because IL-­‐4,
although it is a potent inducer of CCL17, is not essential for its production in vivo: IL-­‐4-­‐deficient
mice did not display the same cross-­‐priming defect as CCL17-­‐deficient mice but gave a similar
response to wild-­‐type mice (Fig. 4.2-­‐2e). Additionally, CCL17 mRNA was present in both wild-­‐
type and IL-­‐4-­‐deficient DCs after αGalCer-­‐treatment as determined by RT-­‐PCR (Fig.4.2-­‐2f).
Taken together these results indicate that expression of CCL17 can be induced by IL-­‐4.
Nevertheless, CCL17 production seems to be a redundant process in which other cytokines can
substitute for IL-­‐4.
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Fig. 4.2-­‐2 Mechanisms of CCL17 induction. Flow cytometric analysis of a fluorescent bead immunoassay
(Bender MedSystems) of NKT cell supernatant from 5x105 cells isolated from wild-­‐type mice injected or
not with 0,2µg αGalCer 5 h previously (a). Flow cytometric analysis of CCL17 expression by DCs isolated
from CCL17eGFP-­‐reporter mice and cultured for 16 h with IL-­‐4, IL-­‐13, TNFα, IFNγ or anti-­‐CD40 (a-­‐CD40)
antibody alone (b) or in combinations as indicated in (c). Summary of the potential of the indicated
cytokines to induce CCL17 in splenic DCs; different levels of gray represent different percentages of
CCL17-­‐producing DCs in steps of 5% (d). OVA-­‐specific cytotoxicity in the spleen on day 5 after priming
wild-­‐type (wt), IL-­‐4-­‐/-­‐ or CCL17-­‐/-­‐ mice with soluble OVA with αGalCer (e). CCL17 mRNA expression in
wild-­‐type and IL-­‐4-­‐deficient DCs 20 h after injection of αGalCer, presented relative to GAPDH RNA
expression (f). Data are representative of three individual experiments (mean + s.d. of three to four mice
per group). *P < 0.05 **P < 0.01 *** P < 0.001 (one-­‐way ANOVA + Dunnets post test (b,e), one-­‐way
ANOVA + Tukey post test (c), Mann-­‐Whitney (f)).
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4.3 Effect of CCL17 on DCs and NKT cells
4.3.1 CCL17 does not alter the cross-­priming ability of DCs
As the boosting effect of αGalCer on CD8+ T cell responses has so far been associated with the
expression of costimulatory molecules on NKT cell-­‐stimulated DCs, I first examined the
influence of CCL17-­‐ and CCR4-­‐deficiency on the upregulation of these molecules. For this
purpose DCs were isolated from wild-­‐type, CCL17-­‐deficient or CCR4-­‐deficient mice that had
been injected with αGalCer or vehicle control 14 h previously and the expression of
costimulatory molecules was determined using flow cytometry. Expression of CD80, CD86 and
CD40 were unaltered in the absence of CCR4 and CCL17 (Fig. 4.3-­‐1a), indicating that “signal 2”
is not influenced by CCL17. Concerning “signal 3” we knew from previous experiments
performed by Veronika Lukacs-­‐Kornek (data not shown), that IL-­‐12 production is indeed
dependent on CCR4 signaling as CCL17-­‐ and CCR4-­‐deficient DCs produced less IL-­‐12.
Nevertheless, p35-­‐/-­‐ mice that lack the p35 subunit, which heterodimerizes with the p40
subunit to form functional IL-­‐12 (63), displayed a similar T cell response as wild-­‐type mice (data
not shown). These results indicate that αGalCer enhances cross-­‐priming independent of IL-­‐12.
To directly investigate if CCL17 influences the stimulatory capacity of DCs, splenic DCs from
αGalCer-­‐injected wild-­‐type or CCR4-­‐deficient mice were loaded with the OVA peptide SIINFEKL
and co-­‐cultured with OT-­‐I cells. Both DC types induced similar T cell proliferation and IFNγ-­‐
production, indicating that CCL17 does not directly alter the stimulatory capacity of DCs (Fig.
4.3-­‐1b). To determine if NKT cells might have a CCL17-­‐dependent direct stimulatory effect on
CD8+ T cell activation, NKT cells from αGalCer-­‐injected wild-­‐type or CCR4-­‐deficient mice were
isolated and cocultured with anti-­‐CD3/anti-­‐CD28-­‐stimulated CD8+ T cells. As the presence of
either wild-­‐type or CCR4-­‐deficient NKT cells had no effect on T cell activation (Fig. 4.3-­‐1c) it
was concluded that NKT cells have no direct stimulatory effect on CD8+ T cell activation but
instead influence the cross-­‐priming ability of DCs by inducing expression of costimulatory
molecules and CCL17. In summary these data demonstrate that CCL17 does not enhance cross-­‐
priming by rendering DCs or NKT cells more stimulatory.
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Fig. 4.3-­‐1 CCL17 does not influence DC and NKT cell functions. Flow cytometric analysis of CD86, CD80
and CD40 expression on splenic DCs from wild-­‐type (wt), CCL17-­‐deficient (CCL17-­‐/-­‐) and CCR4-­‐deficient
(CCR4-­‐/-­‐) mice injected 14 h previously with αGalCer or vehicle (a). Division index (left) and IFNγ-­‐
concentration in culture supernatants (right) from 1.5x 105 OT-­‐I cells cultured for 2 d together with 0.5x
105 wild-­‐type or CCR4-­‐deficient splenic DCs isolated from αGalCer-­‐injected mice and loaded with OVA
peptide (SIINFEKL) (b). Division indices of splenic CD8+ T cells obtained from αGalCer-­‐injected wild-­‐type
mice stimulated with anti-­‐CD3 plus anti-­‐CD28 beads (CD3/CD28) and cultured in the presence or
absence of splenic NKT cells from wild-­‐type or CCR4-­‐deficient mice injected with αGalCer 5 h before (c).
Data are representative of three to four experiments (mean + s.d. of three to four mice per group). MFI,
mean fluorescent intensity.
4.3.2 CCL17 does not increase DC or NKT cell recruitment
Another explanation for enhanced cross-­‐priming due to CCL17 could be enhanced numbers of
cross-­‐presenting DCs or DC-­‐stimulating NKT cells at the site of T cell priming. Hence, DC and
NKT cell numbers were determined in the spleen of mice that had or had not been treated
with αGalCer 5 h previously. However, the results showed no significant increase in DC
numbers after injection of αGalCer and unchanged DC numbers and subset compositions in
CCR4-­‐ and CCL17-­‐deficient spleens compared to wild-­‐type mice (Fig. 4.3-­‐2a). Similarly, NKT cell
numbers were equally high in wild-­‐type and CCR4-­‐deficient spleens (Fig. 4.3-­‐2b). Furthermore,
similar percentages of mature DCs could be found in the spleens of wild-­‐type and CCR4-­‐
deficient mice, indicating that CCL17 does not attract NKT cells to the spleen in order to
increase the number of mature DCs (Fig. 4.3-­‐2c).
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Fig. 4.3-­‐2 CCL17 does not increase DC or NKT cell recruitment. Absolute DC numbers per spleen and
proportions of CD11b+ and CD8+ DCs in wild-­‐type (wt), CCL17-­‐deficient (CCL17-­‐/-­‐) and CCR4-­‐deficient
(CCR4-­‐/-­‐) mice injected 5 h previously with αGalCer (+ α-­‐GC) or vehicle. Total DC numbers per spleen
were defined as 100% (a). Absolute NKT cell numbers per spleen in wt, CCL17-­‐deficient or CCR4-­‐
deficient mice injected 5 h previously with αGalCer or vehicle (b). Flow cytometry of percentage of
CD11c+ cells coexpressing CD40 (c). Data are representative of three experiments (mean + s.d. of three
to four mice per group).
4.3.3 CCL17 positively regulates its own production
Another factor that required investigation was chemokine production itself. Indeed, CCL17
mRNA levels were highly reduced in CCR4-­‐deficient DCs as compared to wild-­‐type DCs,
indicating that CCL17 positively regulates its own production via CCR4 signaling (Fig. 4.3-­‐3a).
Interestingly, the alternate CCR4 ligand CCL22 was expressed by αGalCer-­‐activated NKT cells,
but not by DCs, in a CCR4-­‐dependent manner (Fig. 4.3-­‐3b). Nevertheless, CCL22 seemed to
play no critical role in CCR4-­‐mediated cross-­‐priming as T cell cytotoxicity did not differ greatly
between CCR4-­‐deficient and CCL17-­‐deficient mice (Fig. 4.1-­‐2b). Hence this study concentrated
on the role of CCL17. The fact that CCL17 production was the only factor to be altered in CCR4-­‐
deficient mice led us to believe that CCL17 might act directly on CD8+ T cells, although CCR4
had so far not been associated with CD8+ T cells.
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Fig. 4.3-­‐3 CCL17 positively regulates its own production. CCL17 mRNA (a) and CCL22 mRNA (b)
expression in wild-­‐type and CCR4-­‐deficient DCs or NKT cells 5 h after injection of αGalCer, presented
relative to 18S RNA expression. Data are representative of two experiments (mean and s.d. of three
mice per group) *P < 0.05 **P < 0.01 *** P < 0.001 (student´s t-­‐test (a,b)).
4.4 Effect of CCL17 on CD8+ T cells
4.4.1 CCL17 acts directly on CD8+ T cells
Naïve CD8+ T cells are usually associated with the chemokine receptor CCR7, which coordinates
positioning of naïve CD8+ T cells in T cell zones. However a potential role for the TH2-­‐related
receptor CCR4 has yet to be documented. Therefore, this issue was addressed through
adoptive transfer of CCR4-­‐competent or –deficient OT-­‐I cells into wild-­‐type mice, whereby an
influence of CCL17 on CD8+ T cells could selectively be excluded. Indeed, mice that had
received CCR4-­‐deficient OT-­‐I cells showed significantly reduced cross-­‐priming compared to
mice that had received CCR4-­‐competent OT-­‐I cells (Fig. 4.4-­‐1a). On the other hand, transfer of
CCR4-­‐competent OT-­‐I cells into CCR4-­‐deficient animals could restore cross-­‐priming to similar
levels as observed in wild-­‐type mice (Fig. 4.4-­‐1a). This finding did not result from intrinsic
activation defects of CCR4-­‐deficient OT-­‐I cells because they were activated to the same degree
as wild-­‐type OT-­‐I cells by anti-­‐CD3/anti-­‐CD28 stimulation in vitro (Fig. 4.4-­‐1b).
To confirm the finding that CCL17 improves cross-­‐priming through a direct effect on CD8+ T
cells, mixed bone marrow chimeras were generated in which all cell types except CD8+ T cells
can express CCR4. To achieve this, a 1:1 mixture of bone marrow from CCR4-­‐/-­‐ and CD8-­‐/-­‐ mice
was transferred into irradiated CCR4-­‐deficient recipients. As CD8-­‐/-­‐ mice lack CD8+ T cells, such
mixed chimeras could only generate CD8+ T cells from CCR4-­‐deficient bone marrow (Fig. 4.4-­‐1c
cartoon). Co-­‐injection of OVA with αGalCer into these mice did not increase the numbers of
CD8+ OVA-­‐specific T cells as it did in the control group that received wild-­‐type and CCR4-­‐
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deficient bone marrow. Instead, CD8+ OVA-­‐specific T cell numbers were similar to those in
chimeras that had received only CCR4-­‐deficient bone marrow (Fig. 4.4-­‐1c).
The effect of CCL17 on CD8+ T cell activation was not due to CCL17 acting as a growth factor, as
the addition of CCL17 to cultures of anti-­‐CD3/anti-­‐CD28-­‐stimulated CD8+ T cells did not
enhance T cell proliferation or IFNγ-­‐production (Fig. 4.4-­‐1d). These findings indicate that CCL17
can directly influence CD8+ T cells, however as it does not directly affect T cell activation it may
regulate their migration towards licensed DCs.
Fig. 4.4-­‐1 CCL17 enhances cross-­‐priming by acting directly on CD8+ T cells. In vivo cytotoxicity on day 4
of wild-­‐type and CCR4-­‐deficient mice given 5x 103 CCR4-­‐sufficient or CCR4-­‐deficient OT-­‐I cells and
primed with OVA plus αGalCer (a-­‐GC) 1 d later (a). Division index (left) and IFNγ content in supernatants
(right) of 2x 105 CCR4-­‐competent or CCR4-­‐deficient OT-­‐I cells stimulated for 2 d with anti-­‐CD3 / anti-­‐
CD28 beads (b). Flow cytometric analysis of endogenous OVA-­‐specific CTLs among splenic CD8+ cells of
CCR4-­‐deficient mice reconstituted with 50% CCR4-­‐deficient and 50% wild-­‐type bone marrow, CCR4-­‐
deficient or 50% CD8-­‐deficient and 50% CCR4-­‐deficient bone marrow, assessed 2 d after priming with
OVA plus αGalCer or OVA alone. Cartoon depicts on which cells CCL17 can act in CD8-­‐/-­‐ / CCR4-­‐/-­‐
chimeras (c). Division index (left) and IFNγ content in supernatants (right) of 2x 105 OT-­‐I cells stimulated
for 2 d with anti-­‐CD3 / anti-­‐CD28 beads with or without recombinant CCL17 (600 ng/ml) (e); Data are
representative of two to three experiments (mean and s.d. of four to five mice per group in each). *** P
< 0.001 (one-­‐way ANOVA + Bonferroni multiple comparison post test (a), one-­‐way ANOVA + Dunnet´s
post test (c)).
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4.4.2 αGalCer-­treatment improves the migration of naïve CD8+ T cells towards
CCL17
So far, there have been no reports of CCL17-­‐mediated recruitment of CD8+ T cells. Previous
studies had focused on CCR4 recruitment of DCs and CD4+ T cells. Therefore, I aimed at
confirming that naïve CD8+ T cells are rendered responsive to CCL17 after injection of αGalCer
utilising a transwell assay. For this assay CD8+ T cells were isolated from mice that had received
αGalCer at different time points prior to isolation, or from untreated controls, and their
migration towards 800ng/ml CCL17 was analyzed after 6 h. The percentage of transmigrated
CD8+ T cells increased significantly between 6 and 9 h after αGalCer-­‐injection as determined by
flow-­‐cytometry (Fig. 4.4-­‐2a), notably only under CCL17-­‐stimulated conditions but not in
medium controls. This observation indicated that CD8+ T cells migrate specifically towards
CCL17 instead of randomly increasing their motility.
Live-­‐cell imaging of CCR4-­‐competent or –deficient CD8+ T cells in co-­‐culture with CCL17-­‐
competent or –deficient DCs from αGalCer-­‐injected or untreated mice was performed to
further characterize CCR4-­‐mediated migration of CD8+ T cells. As observed in the transwell
assay, CD8+ T cells from untreated mice (-­‐ α-­‐GC) showed reduced directionality when
migrating towards CCL17-­‐producing DCs from αGalCer-­‐injected mice as compared to CD8+ T
cells from αGalCer-­‐injected mice (Fig. 4.4-­‐2b). This enhancement of directed migration was
dependent on both DC-­‐derived CCL17 and CCR4 on CD8+ T cells, as wild-­‐type CD8+ T cells
showed reduced directionality when co-­‐cultured with CCL17-­‐deficient DCs, as did CCR4-­‐
deficient CD8+ T cells (Fig. 4.4-­‐2b). Interestingly, contact duration between DCs and CD8+ T
cells was also increased in a CCR4-­‐dependent manner (Fig. 4.4-­‐2c). These findings were
confirmed by using tripartite cultures where the directionality and contact duration of CCR4-­‐
competent and –deficient CD8+ T cells in culture with CCL17-­‐producing DCs were compared
(Fig. 4.4-­‐2d,e), or of CCR4-­‐competent CD8+ T cells in culture with both CCL17-­‐competent and –
deficient DCs (Fig. 4.4-­‐2f,g). CCR4-­‐competent CD8+ T cells migrated more accurately towards
CCL17-­‐producing DCs and established longer contacts of approximately 50 minutes, while in
comparison CCR4-­‐deficient CD8+ T cells had an average contact duration of 25 minutes (Fig.
4.4-­‐2d,e). Similarly, CCR4-­‐competent CD8+ T cells migrated more accurately towards CCL17-­‐
producing DCs and established longer contacts than with CCL17-­‐deficient DCs (Fig. 4.4-­‐2f,g). In
summary these results demonstrate that CD8+ T cells are rendered responsive to CCL17 after
injection of αGalCer, which enhances their directional CCR4-­‐dependent migration towards
CCL17-­‐producing DCs.
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Fig. 4.4-­‐2 αGalCer-­‐treatment induces CCR4-­‐dependent migration of CD8+ T cells. Transwell assay of the
migration of polyclonal CD8+ T cells towards CCL17 (800 ng/ml); cells were isolated from mice injected
with αGalCer 3, 6, 9 or 12 h prior to analysis (a). In vitro migration of CD8+ T cells with or without CCR4
expression towards DCs with or without CCL17 production, recorded by time-­‐lapse videomicroscopy
over 2–3 h and presented as CD8+ T cell directionality before physical contact with DCs (b) or
subsequent duration of CTL-­‐DC contact (c). Below graphs: α−GC indicates DCs or CD8+ T cells from donor
mice injected with αGalCer 14 h before (+) or not (–). Numbers adjacent to vertical brackets (c) indicate
percent contacts lasting longer than 40 min. CD8+ T cell directionality (d) and contact duration (e) of
mixed populations of CD8+ T cells with or without CCR4 expression, recorded by time-­‐lapse
videomicroscopy over 2–3 h. CD8+ T cell directionality (f) and contact duration (g) of mixed populations
of DCs with or without CCL17 production, recorded by time-­‐lapse videomicroscopy over 2–3 h. In b–g,
each symbol represents an individual cell (n = 30–40 cells (directionality) or n = 100–300 cells (contact
duration)); small horizontal lines indicate the mean. Data are representative of three experiments (mean
and s.d. of three to four mice per group). n.s., not significant, **P < 0.01 *** P < 0.001 (Kruskal-­‐Wallis
and Dunn’s post-­‐test (b,c) or Mann-­‐Whitney (d–g)).
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4.4.3 CD8+ T cells accumulate in splenic T cell zones following αGalCer-­injection
To determine the physiological relevance of the above findings, I wished to confirm the in vitro
results on CCR4-­‐dependent CD8+ T cell migration in vivo. To this end, immunofluorescence
microscopy of spleen sections was performed where the numbers of CD8+ T cells present in T
cell zones of mice treated with or without αGalCer were compared. FarRed-­‐labeled OT-­‐I cells
were adoptively transferred into CCL17-­‐eGFP reporter mice in order to allow identification of
OVA-­‐specific CD8+ T cells and CCL17-­‐producing DCs. 10 h after challenging the mice with OVA,
αGalCer, or OVA plus αGalCer, spleen sections were stained for B220 to discriminate between
splenic B cell and T cell zones. Counting the number of FarRed-­‐labeled OT-­‐I cells in T cell zones
revealed the presence of more CD8+ T cells in T cell zones in mice that had been co-­‐injected
with OVA and αGalCer compared to mice injected with OVA alone (Fig. 4.4-­‐3a). Importantly
this effect was antigen-­‐independent as T cell numbers were similar in mice that received OVA
plus αGalCer and those that were injected with αGalCer alone (Fig. 4.4-­‐3b). The increase in T
cell numbers depended upon both CCR4 expression on CD8+ T cells and CCL17 production by
DCs as transfer of CCR4-­‐competent OT-­‐I cells into CCL17-­‐deficient mice or transfer of CCR4-­‐
deficient OT-­‐I cells resulted in reduced numbers of CD8+ T cells accumulating in T cell zones as
compared to controls (Fig. 4.4-­‐3c). To ensure that the observed effects were indeed antigen-­‐
independent, the same experiments were performed with polyclonal CD8+ T cells instead of
OT-­‐I cells and indeed also these cells accumulated in a CCR4-­‐dependent fashion (Fig. 4.4-­‐3d).
The same was true when NKT cells were activated by another ligand, namely iGb3 (Fig. 4.4-­‐3e),
demonstrating that CCR4-­‐dependent attraction and accumulation of CD8+ T cells is a general
mechanism that is induced upon activation of NKT cells.
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Fig. 4.4-­‐3 CD8+ T cells accumulate in splenic T cell zones in a CCR4-­‐dependent fashion.
Immunofluorescence staining of spleen cryosections from CCL17-­‐eGFP reporter mice or CCL17-­‐deficient
mice injected with 2.5x 106 FarRed fluorochrome–labeled CCR4-­‐sufficient OT-­‐I cells on day -­‐1 and then
injected with OVA with or without αGalCer on day 0. Blue staining indicates B220+ cells (defines B cell
zones). Scale bars 200 µm (a). Absolute numbers of CCR4-­‐sufficent or CCR4-­‐deficient OT-­‐I cells in CCL17-­‐
deficient or CCL17-­‐eGFP reporter mice 10 h after injection with OVA with or without αGalCer, presented
as cells per mm2 of the T cell–DC zone enclosed by the (blue) B cell zone (b,c). Absolute numbers of
FarRed fluorochrome–labeled polyclonal wild-­‐type or CCR4-­‐deficient CD8+ T cells transferred into
αGalCer-­‐injected CCL17-­‐deficient mice or CCL17-­‐eGFP reporter mice as described in a-­‐c (d). Absolute
numbers of CCR4-­‐sufficent or CCR4-­‐deficient OT-­‐I cells in CCL17-­‐deficient or CCL17-­‐eGFP reporter mice
10 h after injection of iGb3, presented as described in b,c (e). Data are representative of three
individual experiments with at least 25 T cell–DC zones per group derived from three to four
nonconsecutive sections from three mice each (mean and s.d.). n.s., not significant, *** P < 0.001
(Kruskal-­‐Wallis and Dunn’s post-­‐test (b-­‐e)).
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4.4.4 Mechanism of CCR4 induction
As mentioned previously (section 4.1-­‐2), naïve CD8+ T cells are usually not responsive to CCR4
ligands. However as currently demonstrated, the injection of αGalCer and the accompanying
activation of NKT cells not only induced the production of CCL17 in DCs but also enabled the
responsiveness of CD8+ T cells to CCL17 (Fig. 4.4-­‐2, 4.4-­‐3). To discriminate between the
expression of CCR4 being upregulated or the receptor simply being rendered responsive on
CD8+ T cells, CD8+ T cells from wild-­‐type mice were injected with αGalCer at different time
points prior to analysis or from untreated controls for expression of CCR4 by flow cytometry.
Indeed, CCR4 signal was observed in αGalCer-­‐injected mice but not in untreated mice (Fig.4.4-­‐
4a), with levels of CCR4 increasing between 8 h and 14 h after injection and slowly declining at
16 h. These results suggest that CCR4 is upregulated by certain signals that occur after NKT cell
activation and DC licensing. A fluorescent bead immunoassay (Bender MedSystems) was used
to identify which cytokines are present in the spleen after αGalCer-­‐injection that could be
involved in upregulation of CCR4. The assay was performed with supernatants of splenocytes
isolated from untreated or αGalCer-­‐injected wild-­‐type mice and cultured for 24 h in 96 well
plates. These supernatants revealed the presence of IL-­‐4, TNFα and IFNγ, as would be
expected after activation of NKT cells, and the upregulation of IL-­‐6 (Fig. 4.4-­‐4b). IL-­‐6 was
probably produced by endothelial cells or DCs but not NKT cells as isolated NKT cells did not
produce high levels of IL-­‐6 (Fig. 4.2-­‐2a). As regards other DC-­‐derived cytokines that could be
involved in CCR4 induction, high levels of IL-­‐12 were produced by DCs after injection of
αGalCer (data from Veronika Lukacs-­‐Kornek, not shown), thus IL-­‐12 was included in the
analysis.
To investigate the effect of individual factors on upregulation of CCR4, an in vitro assay was
used in which naïve CD8+ T cells were cultured in the presence of the particular reagent(s) for
14 h before analyzing CCR4 expression by flow cytometry. 14 h was chosen as time point as
CCR4 expression peaked around 14 h (Fig.4.4-­‐4a) First, CD8+ T cells were cultured with serum
from mice that had been injected with αGalCer 5 h previously, to determine if a soluble factor
is responsible for CCR4 expression. Indeed, addition of serum induced CCR4 expression in CD8+
T cells (Fig. 4.4-­‐4c). Subsequently, the influence of the individual cytokines at different
concentrations (10 – 200 ng/ml) was determined, but no effect on CCR4 expression with any of
these cytokines was found (Fig. 4.4-­‐4c). Neither the combination of all cytokines, nor the
combination of IL-­‐4 and TFNα, which is able to induce CCL17, induced CCR4 expression on
CD8+ T cells (Fig. 4.4-­‐4d). Since the presence of certain cytokines might have an inhibitory
effect on CCR4 expression, different combinations with 2 or more cytokines were investigated,
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but upregulation of CCR4 was not seen (table 4.4-­‐1). Furthermore, the effect of the CCR4
ligands CCL17 and CCL22 themselves was analyzed, but neither CCL17, CCL22, nor the two
combined could induce expression of CCR4 (Fig. 4.4-­‐4e). In addition, other cytokines that have
been implicated in TH2-­‐related responses (64, 65) were tested, namely IL-­‐33 and TSLP, but they
too had no effect (Fig. 4.4-­‐4d). Table 4.4-­‐1 summarizes all the combinations tested for CCR4
induction. Thus the question remains which signals besides the classical NKT cell and DC-­‐
related cytokines are essential to induce upregulation of CCR4, and further investigation will
be needed to clarify this question.
Table 4.4-­‐1 Cytokine combinations tested for CCR4 expression in CD8+ T cells. Single cytokines were
applied at different concentrations for 14 h on 2x105 naïve CD8+ T cells isolated from wild-­‐type spleens.
Cytokine concentrations in combinations were used at the highest concentrations tested for each
cytokine.
Cytokine stimulus Cytokine stimulus Cytokine stimulus
IFNγ 10/100/200 ng/ml IL4+TNFα IL4+IL12+IL2+IL33
IL4 10/100/200 ng/ml TNFα+IL2 IL6+IL12+IL2
IL13 10/100/200 ng/ml TNFα+IL6 IL6+IL2+IL4
TNFα 10/100/200 ng/ml TNFα+IL12 IL2+IL4+TNFα+IFNγ+IL6
IL2 10/100/200 ng/ml TNFα+IFNγ IL2+IL4+TNFα+IFNγ+IL12
IL12 10/100/200 ng/ml IL2+IFNγ IL2+IL4+TNFα+IL12+IL6
IL6 10/100/200 ng/ml IL2+IL6 IL2+IL4+IL12+IFNγ+IL6
TSLP 10/100/200 ng/ml IL2+IL12 IL2+IL12+TNFα+IFNγ+IL6
IL15 10/100/200 ng/ml IL2+TSLP IL12+IL4+TNFα+IFNγ+IL6
IL33 10/100/200 ng/ml IL2+IL15 IL2+IL4+TNFα+IFNγ+IL6+IL12+TSLP
CCL17200/600/1000 µg/ml IL2+CCL17 IL2+IL4+TNFα+IFNγ+IL6+IL12+CCL17
CCL22 200/600/1000 µg/ml IL2+IL33 IL2+IL4+TNFα+IFNγ+IL6+IL12+CCL22
GM-­‐CSF IL6+IL12 IL2+IL4+TNFα+IFNγ+IL6+IL12+IL33
IL4+IFNγ IL6+IFNγ IL2+IL4+TNFα+IFNγ+IL6+IL12+IL15
IL4+IL2 IFNγ+IL12 IL2+IL4+TNFα+IFNγ+IL6+IL12
IL4+IL12 IL4+TNFα+IL12 TSPL+CCL17
IL4+IL6 IL4+IFNγ+IL12 TSPL+CCL22
IL4+TSLP IL4+TNFα+IL2 TSLP+IL4+TNFα
IL4+IL33 IL4+IL2+CCL22 IL4+IL2+TNFα+IL12
IL4+CCL17 IL4+IL2+TNFα+CCL17
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Fig. 4.4-­‐4 Regular NKT cell and DC cytokines do not induce CCR4 expression. Flow cytometric analysis
of CCR4 expression on splenic CD8+ T cells from wild-­‐type mice injected 4,8,14 or 16 h previously with
αGalCer (a). Flow cytometric analysis of a fluorescent bead immunoassay (Bender MedSystems) of NKT
cell supernatant from 5x105 cells isolated from wild-­‐type mice injected or not with 0,2µg αGalCer 5 h
previously (b). CCR4 expression of CD8+ T cells isolated from untreated wild-­‐type spleens and cultured
with serum from αGalCer-­‐treated wild-­‐type mice or different cytokines for 14 h before analysis by flow
cytometry (c-­‐e). MFI: mean fluorescence intensity.
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4.5 Synergistic effect of classical and alternative DC licensing
4.5.1 Combination of classical and alternative DC licensing boosts cross-­priming
The data presented so far suggested that NKT cell-­‐mediated DC licensing is a pathway that
operates separately from classical DC licensing and is regulated by distinct chemokine signals.
To confirm that CCR4 regulates CD8+ T cell attraction after NKT cell-­‐mediated DC licensing, but
not attraction after classical licensing, histological analyses were performed. Indeed, CCR4-­‐
deficient T cells failed to accumulate after injection of OVA plus αGalCer but not after injection
of OVA plus CpG (Fig. 4.5-­‐1a), confirming the involvement of CCR4 in attraction of CD8+ T cells
in NKT cell-­‐mediated cross-­‐priming but not in classical cross-­‐priming. On the other hand, CCR5-­‐
deficient T cells accumulated in spleens after injection of OVA plus αGalCer but not after OVA
plus CpG (Fig.4.5-­‐1b), indicating that CCR5 regulates classical cross-­‐priming rather than NKT
cell-­‐mediated cross-­‐priming.
These findings raise the question how a combination of classical and NKT cell mediated DC
licensing would affect cross-­‐priming. This question was addressed in an in vivo cytotoxicity
assay to compare the T cell response after DC licensing in the presence of glycolipids, TLR
ligands or both. Wild-­‐type mice that were challenged with OVA plus maximally effective doses
of αGalCer plus CpG displayed a significantly better cytotoxic T cell response compared to mice
that received OVA plus αGalCer or CpG alone. This was true for T cell responses in both the
spleen after intravenous injection of αGalCer (Fig. 4.5-­‐1c) and in the draining lymph node after
subcutaneous injection (Fig. 4.5-­‐1d). These results demonstrate that the combined effect of
DC licensing by NKT cells and TH cells synergize and result in an even better T cell activation.
To analyze how chemokine-­‐signals are involved and if the augmented CD8+ T cell response is
accompanied by augmented attraction of CD8+ T cells, T cell numbers in the splenic T cell zone
were dissected as described in Figure 4.4-­‐3. When adoptively transferred OT-­‐I cells that are
competent for both CCR4 and CCR5 were transferred, they accumulated in higher numbers
after co-­‐injection of OVA plus αGalCer plus CpG compared to injection of OVA plus αGalCer or
CpG alone (Fig. 4.5-­‐1e). These data indicate that the synergy of classical and NKT cell-­‐mediated
cross-­‐priming is at least in part achieved by improved attraction of CD8+ T cells.
To clarify how the enhanced attraction of CD8+ T cells is mediated, the chemokine production
by DCs was investigated in more detail. Histological results had shown that OVA plus CpG-­‐
induced DC licensing is independent of CCL17-­‐ CCR4 signals (Fig. 4.5-­‐1a). Nevertheless, a
possible influence of co-­‐injection of CpG and subsequent activation of TLR9 on CCL17 levels
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had to be excluded. Thus, CCL17eGFP-­‐reporter mice were analyzed for the percentage of DCs
expressing CCL17 after injection of OVA plus αGalCer and of OVA plus αGalCer plus CpG, but
similar percentages of DCs upregulating CCL17 were found (Fig. 4.5-­‐1f). Also the amount of
CCL17 produced per DC was similar with or without co-­‐injection of CpG (Fig. 4.5-­‐1g).
To clarify if CCL17 and CCR5 ligands are produced by two distinct DC subsets and therefore
more DCs might attract CD8+ T cells, DCs were isolated from CCL17eGFP-­‐reporter mice that
had been injected with OVA plus αGalCer plus CpG, and sorted DCs expressing CCL17 (=
CD11c GFP ) or not (= CD11c GFP−). When these two subsets were examined for expression of
CCR5 ligands by RT-­‐PCR, CCL17-­‐expressing DCs were found to co-­‐express high levels of CCL3
and especially CCL5 (Fig. 4.5-­‐1h). These results indicate that similar numbers of DCs are able to
attract T cells after classical DC licensing, NKT cell mediated DC licensing and the combination
of both. Thus remains to be investigated whether CCL17 and CCR5 ligands attract different
subsets of CD8+ T cells. The combined attraction of two different subsets might explain higher
T cell numbers after the combined induction of both chemokine pathways.
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Fig. 4.5-­‐1 Combination of classical and NKT cell mediated cross-­‐priming induce even better T cell
responses. Absolute number of adoptively transferred CCR4-­‐deficient (a) or CCR5-­‐deficient (b) in OVA-­‐
primed wild-­‐type mice coinjected with αGalCer, CpG or both, assessed by histology as described in
Figure 4.4-­‐3 (presented as cells per mm2 of the T cell–DC zone). OVA-­‐specific cytotoxicity in the spleen 5
d after priming wild-­‐type mice with soluble OVA plus αGalCer and/or CpG intravenously in spleen (c).
Flow cytometric analysis of the proportion of OT-­‐I cells in splenic CD8+ cells in the draining lymph node 3
d after subcutaneous injection of soluble OVA plus αGalCer and/or CpG (d). Absolute number of
adoptively transferred wild-­‐type OT-­‐I T cells (e) in OVA-­‐primed wild-­‐type mice coinjected with αGalCer,
CpG or both, assessed by histology as described in Figure 4.4-­‐3 (presented as cells per mm2 of the T cell–
DC zone). Flow cytometry of spleen cells from CCL17-­‐eGFP reporter mice 20 h after injection of OVA plus
αGalCer with or without CpG, with gating on CD11c+CCL17+cells (f,g). CCL3, CCL4 and CCL5 mRNA
expression in CCL17-­‐negative (CCL17-­‐) and CCL17-­‐producing (CCL17+) DCs 20 h after injection of
αGalCer, presented relative to GAPDH RNA expression (h); Data are representative of two experiments
(mean and s.d. of three to four mice per group in each). *P < 0.05 *** P < 0.001 (One-­‐way ANOVA +
Tukey post test (c,d), Kruskal Wallis + Dunn´s selected pairs (a,b,e).
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5 Discussion
The NKT cell ligand α-­‐galactosylceramide (αGalCer) has long been known for its adjuvant effect
in enhancing tumor immunity (25). Initial studies demonstrated that injection of αGalCer could
promote the survival of mice with melanoma (66), and NKT cell-­‐deficient mice showed an
increased susceptibility to methylcholanthrene-­‐induced tumors (67). The exact mechanisms
how NKT cells control anti-­‐tumor responses remain unclear. However, direct recognition of
tumor cells by NKT cells is not crucial for tumor rejection as CD1d-­‐deficient tumors can be
rejected in wild-­‐type mice (68). Instead, NKT cells enhance tumor resistance indirectly by
positively regulating functions of other cells, for example DCs. Several studies demonstrated
that NKT cell activation by αGalCer resulted in DC maturation and in a subsequent boost of T
cell responses. Thus, coinjection of αGalCer with a relevant antigen can be used to expand
antigen-­‐specific responses (26,69,70,71). These results provided the foundation for the design
of DC-­‐based immunotherapeutic protocols to potentiate immune responses against tumors
and pathogens. Indeed, injection of αGalCer-­‐loaded DCs improved T cell responses and
attenuated tumor growth in clinical trials (72,73,74). However, the results obtained are not
ideal as the beneficial effects of DC transfer on the disease severity could be observed in only
few patients whereas most patients did not benefit from the improved T cell response. Further
understanding the mechanisms how NKT cells expand immune responses might help to
improve tumor therapy as well as vaccination strategies against a range of pathogens like
malaria and other intracellular pathogens (71). Thus, the present study wanted to clarify the
events underlying NKT cell-­‐mediated DC maturation.
5.1 Role of CCL17 and CCR4 in NKT cell-­mediated cross-­priming in the
spleen
5.1.1 Adjuvant effect of NKT cell activation on cross-­priming
Co-­‐injection of the glycolipid αGalCer with the cross-­‐presented antigen OVA has been
demonstrated to have an adjuvant effect on CD8+ T cell responses (26-­‐28, 71), which was
confirmed in the present study. The events underlying this adjuvant effect have only been
partially described in the literature. Presentation of αGalCer by DCs leads to activation of NKT
cells, resulting in rapid cytokine production and upregulation of CD40L by NKT cells. In turn,
the activated NKT cells induce upregulation of costimulatory molecules on the antigen-­‐
presenting DC via cytokine signals and CD40 signaling (26-­‐28). Fujii et al. (28) attributed the
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adjuvant effect of αGalCer to the mature state of the DCs, as costimulation is believed to
initiate and amplify T cell priming. In line with this interpretation, Hermans et al. suggested
that the adjuvant effect depended on simultaneous presentation of αGalCer and OVA by the
same DC, as the mature state of the cross-­‐presenting DC could increase CD8+ T cell responses
(26). They addressed this issue by analyzing CD8+ T cell responses after transfer of antigen-­‐
loaded DCs. DCs loaded with both αGalCer and OVA induced highly increased T cell responses,
whereas transfer of a mixture of αGalCer-­‐loaded and OVA-­‐loaded DCs did not enhance T cell
activation (26). To clarify this issue in the present study, mixed bone marrow chimeras were
generated that possessed DCs that could present antigen to either NKT or CD8+ T cells but not
to both cell types simultaneously due to a lack of functional MHC-­‐I or CD1d respectively. These
mice were unable to enhance CD8+ T cell responses after co-­‐injection of OVA with αGalCer.
These data confirm that NKT cell activation results in cognate DC licensing. However, not only
the expression of costimulatory molecules but the additional expression of the chemokine
CCL17 by the cross-­‐presenting DC efficiently enhanced CD8+ T cell responses as demonstrated
again in mixed bone marrow chimeras. These chimeras possessed both DCs that could present
simultaneously to both NKT and CD8+ T cells but could not produce CCL17, as well as DCs that
could produce CCL17 but could not cross-­‐present peptide-­‐antigens to CD8+ T cells. These mice
displayed a highly reduced CD8+ T cell response, demonstrating that CCL17 expression by
cross-­‐presenting cells highly increases CD8+ T cell responses.
Thus, the present study presents a new aspect of DC licensing by showing that activated NKT
cells not only induce expression of costimulatory molecules by DCs, but also expression of the
chemokine CCL17. Moreover, it demonstrates that the induction of this chemokine is a crucial
component of DC licensing and is critical for the efficiency of CD8+ T cell responses. Thus not
only the expression of costimulatory molecules but also the expression of chemokines by
cross-­‐presenting DCs strongly influences CD8+ T cell responses and accounts for the majority of
the adjuvant effect of αGalCer.
5.1.2 CCL17 expression in the spleen
CCL17 is expressed as a homeostatic chemokine in the thymus, lymph nodes, lung and
intestine, and its expression can be augmented in these organs by treatment with microbial
agents such as TLR ligands. In contrast, splenic DCs have been demonstrated to lack CCL17
expression, even after systemic microbial challenge (45). The data presented here show that
CCL17 can be induced in splenic DCs by activation of NKT cells through injection of glycolipid
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antigens like αGalCer. Expression of the second CCR4 ligand CCL22 was found in NKT cells but
not DCs after αGalCer-­‐treatment. As reported for CCL5, which amplifies its own expression
(75), both CCL17 and CCL22 enhanced their own production in a CCR4-­‐dependent fashion. The
individual role of the less well characterized CCL22 remains unclear, as does the question
whether the two CCR4 ligands interact in shaping the immune response in NKT cell-­‐mediated
cross-­‐priming. In fact, it seems that CCL17 is the major mediator of CCR4-­‐dependent attraction
of CD8+ T cells as the cytotoxic T cell response was mostly reduced in CCL17-­‐deficient mice and
the differences between CCR4-­‐ and CCL17-­‐deficient mice were not significant. It has been
described previously that chemokines can have differential effects although they signal
through the same receptor. For example CCL19 and CCL21, the two CCR7 ligands, are known to
exert differential signaling effects, as CCL19 induces CCR7 phosphorylation and internalization,
thereby causing receptor desensitization, which is not the case for CCL21 (76). In this way
CCL19 desensitizes cells in their responsiveness towards CCL21 signals. As DCs express CCL19,
this effect could be crucial to stop T cells at antigen-­‐presenting cells rather than to allow
continued migration towards CCL21-­‐producing endothelial cells. The expression by different
cell types suggests that CCL17 and CCL22 also act differentially, but their individual roles and
how they might interact needs to be clarified.
Several studies have investigated the prerequisites for CCL17 induction, with results varying
considerably depending on the investigated cell type: Langerhans cells were described to
produce CCL17 in response to the cytokines IL-­‐4 and TNFα, whereas IFNγ inhibited its
expression (77,78). In contrast, studies with the human keratinocyte cell line HaCaT found
CCL17 induction after the combined application of TNFα and IFNγ, which could be inhibited by
IL-­‐4 (79,80). The fibroblast cell line NG1RGB responded again differently: the combination of
IL-­‐4 and TNFα induced CCL17 expression and could be further increased by IFNγ (80). The
present study demonstrates that IL-­‐4 potently induced CCL17 expression in splenic DCs and
that TNFα further increased this effect, although TNFα alone had only a minor effect on CCL17
expression. IFNγ had an inhibitory effect on CCL17 expression and could completely suppress
CCL17 expression induced by the combination of IL-­‐4 and TNFα.
Regarding IFNγ, it seems counter intuitive that a cytokine, which is usually associated with the
progression of CD8+ T cell responses, has an inhibitory effect on chemokine expression and the
subsequent initiation of cross-­‐priming. Nevertheless, Xiao et al. (77) described a similar
inhibitory effect of IFNγ on CCL17 expression in Langerhans cells. As CCL17 is a chemokine that
is involved in TH2 diseases of the skin, they suggested that CCL17 inhibition by the TH1 cytokine
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IFNγ and stimulation through the TH2 cytokine IL-­‐4 could be an amplification circuit that
increases CCL17 production in the TH2 cytokine microenvironment of the skin in diseases like
atopic dermatitis. As NKT cells are able to secrete both TH1 and TH2 cytokines simultaneously,
the polarization of immune responses is more complex in NKT cell-­‐mediated cross-­‐priming in
the spleen, and a classification into TH1 and TH2 cytokines might not be adequate.
Furthermore, NKT cell-­‐derived IFNγ might affect cross-­‐priming differently than CD8+ T cell-­‐
derived IFNγ as it is present during the early licensing events. Thus, it might influence other
cellular functions, for example the cross-­‐priming ability of DCs rather than CD8+ T cell
proliferation.
However, the in vivo relevance of NKT cell-­‐derived IFNγ in DC licensing remains unclear and
various aspects like IFNγ-­‐receptor expression or delayed IFNγ production might regulate its
impact. To address these questions, it would be necessary to further characterize both the
kinetics of expression of NKT cell-­‐derived IFNγ and of the IFNγ receptor. Regarding IFNγ
expression, several studies previously demonstrated an early burst of IL-­‐4 that is followed by
delayed production of IFNγ (81,32). From these data it could be hypothesized that IFNγ might
act by down-­‐modulating CCL17 expression after the initial CCL17 induction through IL-­‐4 and
TNFα. However, this hypothesis requires testing by the experiments outlined above and
additional experiments using IFNγ-­‐deficient mice.
Although I found IL-­‐4 to be the most potent inducer of CCL17, it was not essential for CCL17
expression, as DCs isolated from αGalCer-­‐treated wild-­‐type or IL4-­‐deficient mice produced
similar levels of CCL17 mRNA. Furthermore, IL-­‐4-­‐deficient mice did not show the same cross-­‐
priming defect observed in CCL17-­‐deficient mice. Interestingly OCH, a synthetic derivate of
αGalCer that is known to selectively induce IL-­‐4 as opposed to IFNγ, induced lower levels of
CCL17 expression as compared to αGalCer. This was unexpected, as higher concentrations of
IL-­‐4 were anticipated to increase CCL17 expression, and reduced IFNγ production should
further enhance CCL17 induction due to reduced inhibition. However, the in vivo situation is
certainly much more complex than the conditions generated in vitro, and thus we might have
failed to detect the contribution of certain factors that shape CCL17 expression in vivo.
Although certain cytokines can induce CCL17 production in vitro, they might not be the critical
agents in vivo, for example due to an inhibitory effect of another factor. Thus, these data
indicate that regulation of CCL17 expression is a process that involves various cytokine signals
and understanding it in more detail will need further investigation. One approach to further
the understanding of CCL17 induction in DCs by NKT cells could be to investigate NKT cell
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subsets in vivo. The mouse has αGalCer-­‐reactive CD4+CD8-­‐ and CD4-­‐CD8-­‐ NKT cell subsets that
can additionally differ in their expression of NK1.1, and even the presence of a CD4-­‐CD8+
subset has been suggested (82). Recently it has become more and more apparent that the
different NKT subsets can carry out different functions. For instance, cytokine production
differs highly depending on expression of CD4 and NK1.1, and on the organ the cells were
isolated from (29, 38, 83). Defining the NKT cell subset that is responsible for CCL17 induction
and analyzing its cytokine profile might give a clearer picture of the factors that regulate CCL17
expression in the spleen.
Besides cytokines, the mast cell mediators histamine and prostaglandin E2 have been described
to have an influence on expression of CCR4 ligands, as they upregulate the production of
CCL17 and CCL22 in immature human DCs (84). These results are especially relevant for allergic
responses in skin or airways where DCs are in close contact with mast cells. Whether these
mediators also play a role in CCL17 induction in the spleen needs to be tested.
In addition to soluble factors, cell surface molecules might be involved in CCL17 induction as
DCs establish close contacts with NKT cells. Signaling through CD40 has been described to play
an important role in DC licensing and is required for the development of immunity (26). So far,
it has not been determined by which pathway CD40L – CD40 interactions exert this effect. Fujii
et al. analyzed the influence of CD40 signaling on the expression of costimulatory molecules
and cytokines, however CD40-­‐deficient mice upregulated CD80 and CD86 to the same degree
as wild-­‐type mice in response to αGalCer (28). Instead, upregulation of CD80/86 depended on
cytokine signals such as TNFα. Although CD40 signaling induced IL-­‐12 production (28, 85), this
factor was not essential for an efficient NKT cell-­‐mediated cross-­‐priming (28, data generated
by Veronika Lukacs-­‐Kornek, not shown). Hence, CD40 signaling must induce other signals apart
from signals 2 and 3. As additional chemokine signals are required for the development of
immunity, the influence of CD40 stimulation on CCL17 expression was addressed in an in vitro
assay. However, DC-­‐stimulation through CD40 had no effect on CCL17 expression in vitro,
though one has to consider that untreated DCs were used that had not yet fully upregulated
CD40. To fully resolve this issue, one would need to investigate CCL17 expression in vivo in
CD40-­‐ or CD40L-­‐deficient mice, or in mice treated with a blocking anti-­‐CD40-­‐antibody.
Taken together, these results demonstrate that the expression of CCL17 in splenic DCs is
induced by IL-­‐4, whereas IL-­‐13, especially in combination with TNFα, can perform the same
function and might be able to substitute for IL-­‐4. IFNγ on the other hand inhibits CCL17
expression. If additional factors are involved in CCL17 induction could be further investigated
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by blocking both IL-­‐4 and IL-­‐13 in vivo. As this study focused on the role of CCL17, it remains
unclear by which signal CCL22 expression is induced in NKT cells. Future studies should address
the question of induction and function of CCL22 to obtain a complete picture of the functions
of CCR4 ligands in cross-­‐priming.
5.1.3 Effect of CCL17 on the cross-­priming ability of DCs
Although chemokines are best known for their role in regulating cell migration, it is evident
that they can also modulate T cell responses independent of their chemoattractant activities.
Thus, several studies have described an involvement of chemokines in DC maturation. The
CCR7 ligands CCL19 and CCL21 have been demonstrated to induce maturation in DCs migrating
from peripheral organs to secondary lymphoid organs where they present their captured
antigen. This process ensures that antigen is presented to naïve T cells in an optimal context.
Similarly, CCL3 (86) and CCR2 (87) have been implicated in the upregulation of the maturation
markers CD80, CD86 and CD40. CCL5 has been demonstrated to induce production of
cytokines such as TNFα and IL-­‐6, and of chemokines like CXCL2, CCL3, CCL4 and CCL5 in
immature bone marrow derived DCs (BMDCs) (75). So far, there are no reports on CCL17-­‐
mediated induction of DC maturation markers, but there is a striking connection between
CCL17 expression and upregulation of costimulatory molecules, in that IL-­‐4 and TNFα do not
only play an important role in induction of CCL17 but also in the induction of costimulatory
molecules such as CD80 and CD86 (26, 77). These data led to the hypothesis that IL-­‐4 and
TNFα might induce the expression of costimulatory molecules indirectly through induction of
CCL17 expression, which in turn might upregulate CD80/86 expression. However, I found that
expression of costimulatory molecules was unaltered in CCR4-­‐ and CCL17-­‐deficient mice,
demonstrating that CCL17 does not influence the expression of costimulatory molecules in
cross-­‐presenting DCs.
However, the overall cross-­‐priming ability of DCs might be influenced by factors other than
CD80/86 and CD40 expression, hence the cross-­‐priming capacity of DCs that had been licensed
in αGalCer-­‐injected CCR4-­‐competent or CCR4-­‐deficient mice was analyzed ex vivo. As both cell
types induced similar CD8+ T cell responses, it could be concluded that CCL17 has no direct
influence on the cross-­‐priming ability of DCs and is likely to increase cross-­‐priming efficiency by
affecting cell migration.
To investigate if CCL17 enhances CD8+ T cell responses by attracting higher numbers of DCs to
the spleen in NKT cell mediated cross-­‐priming, the number and subset composition of DCs in
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the presence or absence of CCL17 was compared. However, there was no difference in DC
numbers and subsets, and also the attraction of higher numbers of NKT cells into the spleen
could be excluded. Nevertheless, these experiments cannot exclude an altered distribution of
cells inside the spleen, as more resident DCs or NKT cells might be recruited to the place of
NKT cell – DC interactions. However, similar percentages of mature DCs were present in CCR4-­‐
competent and CCR4-­‐deficient mice, arguing against a CCR4-­‐dependent increase of DC – NKT
cell interactions and a subsequently increased number of licensed DCs. These results
demonstrate that the frequency of NKT cell – DC interaction is unaltered in CCR4-­‐deficient
mice, as is the overall cross-­‐priming capacity of licensed DCs. Furthermore, NKT cells might
directly activate CD8+ T cells as suggested by Matsuda et al. (88). One pathway through which
NKT cells could influence cross-­‐priming directly may be type-­‐I IFN as it can be produced by NKT
cells and has been described to have a direct effect on CD8+ T cell activation (89). However, the
presence of NKT cells from αGalCer-­‐treated CCR4-­‐competent or CCR4-­‐deficient mice did not
affect CD8+ T cell activation in vitro.
Taken together, these results argue against a CCL17-­‐mediated alteration of NKT cell functions
or the cross-­‐priming capacity of DCs, and show that CCL17 does not influence the recruitment
of DCs or NKT cells into the spleen.
5.1.4 CCL17-­responsiveness of CD8+ T cells
Naïve CD8+ T cells are known to express CCR7 and to upregulate CCR5 under inflammatory
conditions (54,56). The data presented in this thesis demonstrate that naïve CD8+ T cells can
become responsive to ligands of the chemokine receptor CCR4 after injection of αGalCer. In
general there are two major mechanisms for chemokine receptor regulation. First, the
responsiveness of a chemokine receptor can be regulated by sensitization as demonstrated for
CCR7 and CXCR4 that can be sensitized by CCL17 signals (53), or desensitization, where
receptors are internalized after ligand binding (90). Second, responsiveness can be regulated
by up-­‐ or down-­‐regulation of a certain receptor (90). Flow-­‐cytometric analysis of CD8+ T cells
revealed that CCR4 is present on αGalCer-­‐treated but not untreated CD8+ T cells, suggesting
that CCR4 is upregulated by a signal that is produced during αGalCer-­‐mediated NKT cell
activation and DC licensing.
Several studies have described that microenvironmental signals, especially pro-­‐ and anti-­‐
inflammatory cytokines, are responsible for down-­‐ or upregulation of chemokine receptors
(91). As high amounts of cytokines are produced rapidly after NKT cell activation, we
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hypothesized that cytokines produced by activated NKT cells or licensed DCs might be
responsible for CCR4 induction. Soluble signals seemed obvious candidates to induce CCR4
expression, as they could influence chemokine receptor expression at a distance and facilitate
cellular attraction towards CCL17-­‐producing DCs. Indeed, CCR4 expression could be induced in
naïve CD8+ T cells after coculture with serum from αGalCer-­‐treated mice, indicating that a
soluble mediator that is released into the circulation of injected mice can influence CCR4
production. However, no upregulation of CCR4 was detected on naïve CD8+ T cells after
treatment with any conventional cytokine produced by activated NKT cells or DCs, or with a
combination of these cytokines.
Although the involvement of the CCR4 ligands themselves seemed unlikely, the effect of CCL17
and CCL22 on CCR4 induction was investigated as they might act independently of CCR4
expression on CD8+ T cells by binding to an as yet unidentified receptor (whose existence has
been suggested previously (52, 53)). However, neither the individual chemokines nor their
combination altered CCR4 expression in vitro. Yet, these results cannot exclude an indirect
effect of CCL17 or CCL22 in vivo, as they might bind to CCR4-­‐expressing cells like NKT cells or
DCs to induce expression of unidentified mediators that could in turn influence CCR4
expression in CD8+ T cells. Analysis of CCR4 induction in CCL17-­‐deficient mice could clarify if
CCL17 has an indirect impact on the expression of CCR4.
Furthermore, the investigated classical cytokines might be indirectly involved in regulation of
CCR4 expression as they might affect other cell types, which in turn could produce the critical
agent for CCR4 induction. This agent could be a factor expressed by non-­‐hematopoietic cells
inside of T cell zones or at the place of T cell entry, the marginal zone bridging channels. Thus,
soluble mediators related to TH2 responses that can be expressed by non-­‐hematopoietic cells
were investigated for their influence on CCR4 expression. Thymic stromal lymphopoietin (TSLP)
can be produced by epithelial cells in asthma, but this factor did not affect CCR4 expression in
our setting. Also the TH2-­‐related cytokine IL-­‐33, which can be expressed by several cell types
including endothelial cells (92), had no effect on CCR4 expression. Many cell types could
function as mediators in CCR4 induction as NKT cell-­‐derived cytokines have been described to
be able to influence a variety of cell types, including NK cells, neutrophils and eosinophils (89).
Also cells that are situated at the site of T cell entry into splenic T cell zones could be involved,
as they would be at the ideal position to induce CCR4 expression on immigrating CD8+ T cells.
These sites are the marginal zone bridging channels (MZBC), which represent breaks in the
marginal sinus. Various cell types, including T cells, are thought to enter the splenic white pulp
at these sites through interactions with Fibroblastic Reticular Cells (FRC) that line the MZBC
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and function as a kind of access road (93). FRCs but also other cell types in this area might be
able to directly interact with naïve CD8+ T cells. Additionally there is a strong correlation
between NKT cells, mast cells and CCL17 expression, which are all major mediators of asthma
development (94, 95). Hence, it would be interesting to investigate the effect of mast cell-­‐
derived mediators on CCR4 expression, especially as histamine and prostaglandin E2 were
described to upregulate expression of the CCR4 ligands CCL17 and CCL22 (84).
Taken together, these results suggest that CCR4 expression on CD8+ T cells is regulated by a
factor or a combination of factors apart from the traditional NKT cell-­‐associated cytokines.
What factor it is and which cell it is expressed by requires clarification in further experiments in
order to fully understand the regulation of chemokine signals in cross-­‐priming.
5.1.5 Chemokine-­dependent regulation of cellular interactions in DC licensing
Naïve CD8+ T cells need to receive several stimulatory signals provided by DCs to become
activated. Thus, a rare antigen-­‐specific CD8+ T cell needs to encounter a mature DC presenting
its specific antigen. Such cellular interactions are typically regulated by chemokines. The best-­‐
described example is CCR7, which coordinates attraction of both antigen-­‐presenting DCs and
naïve T cells into the T cell zone of secondary lymphoid organs (SLOs) (54). By attracting both
cell types to the same compartment inside of SLOs, CCR7 highly increases the likeliness of an
encounter between a naïve T cell and its cognate antigen on a DC.
The correct positioning of immune cells is particularly important in classical and NKT cell-­‐
mediated cross-­‐priming that depend on the interaction of three different cell types. In these
cross-­‐priming events, CD8+ T cells are attracted in a second step following the successful
presentation of antigen to a CD4+ TH cell or an NKT cell. This “secondary” attraction of CD8
+ T
cells is regulated by CCR5 in classical cross-­‐priming, as the antigen-­‐specific interaction between
a CD4+ TH cell and a DC results in expression of the CCR5 ligands CCL3, CCL4 and CCL5 (57) . By
a yet unknown mechanism, naïve CD8+ T cells upregulate CCR5 and are thus attracted towards
the licensed DCs.
The present study identified CCR4 as the chemokine receptor regulating NKT cell-­‐mediated
cross-­‐priming, as it attracted naïve CD8+ T cells towards CCL17-­‐producing DCs that had been
licensed by NKT cells. Thus, CCR5 and CCR4 not only locate DCs and CD8+ T cells to the same
compartment inside of SLOs, they also actively recruit CD8+ T cells to sites of DC licensing
where mature, antigen-­‐presenting DCs can readily prime naïve CD8+ T cells. This directed
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migration highly enhances the efficiency of CD8+ T cell responses, probably due to a faster
attraction and activation or the attraction and activation of higher numbers of CD8+ T cells.
However, this idea also poses conceptual questions: The fact that CD8+ T cells are attracted in
an antigen-­‐independent fashion implies that T cells of random antigen specificity are recruited
towards licensed DCs. This suggests an overabundance of naïve CD8+ T cells accumulating at a
single DC, which would hamper access to the antigen-­‐presenting DC for the relevant antigen-­‐
specific CD8+ T cell. CD8+ T cells would have to leave as quickly as they arrive to make room for
other cells. In contrast, the results from in vitro migration experiments suggest that CCL17
signaling increases contact duration even in the absence of antigen. The absence of either
chemokine receptor expression or CCL17 production reduced contact duration significantly.
One scenario that could explain the discrepancy between the in vitro data and the proposed in
vivo problem could be the expression of a certain signal, which was not present in in vitro
cultures, that decreases contact duration when the presented antigen is not recognized by the
T cell. This signal might be induced by an additional cell type that interacts with DCs and / or T
cells in vivo, one obvious candidate being the NKT cell that licenses the DC. One could envisage
a scenario where NKT cells induce the expression of a certain factor by DCs that inhibits T cell
adhesion, until the DC receives signals from antigen recognition by a specific TCR, for example
via MHC-­‐I. This factor could for example act by modulating the function of the T cell adhesion
molecule LFA-­‐1. This hypothesis could be tested by FACS staining for the active form of LFA-­‐1
or microscopically analysis of LFA-­‐1 clustering. However, the in vitro experiments did not
compare antigen-­‐specific and antigen-­‐unspecific interactions, and interactions in the presence
of antigen might be even longer. Visualizing the in vivo events by two-­‐photon microscopy
could help to clarify the dynamics of DC – CD8+ T cell contacts.
However, it is known that chemokines influence CD8+ T cell priming not only by guiding CD8+ T
cells to the site of antigen-­‐presentation, but also by modulating the interaction between T cells
and DCs. Friedman et al. demonstrated that surface-­‐bound CCL21 prolonged cell contacts (96),
during which T cells can scan the DC surface. This long-­‐lasting contact was necessary to ensure
the sustained signaling that maintains gene transcription and promotes T-­‐cell-­‐cycle
progression (97). Thus, prolonged contact duration due to chemokine signals also has positive
implications, and might nevertheless be involved in mediating efficient T cell responses in vivo.
The need for rapid dissociation from the CCL17-­‐producing DC might not be as profound as one
might assume, as the amount of T cells accumulating at a given time point might be limited by
the fact that only 15-­‐20% among all naïve CD8+ T cells upregulated CCR4. However, if
upregulation of CCR4 was limited due to the concentration of the factor that upregulates this
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chemokine receptor or due to CD8+ T cell intrinsic properties that allow upregulation in only a
subset of T cells needs to be further investigated and might provide insights into the regulation
of chemokine receptors in T cell subsets. Determining the factors that induce expression of
CCR4 on CD8+ T cells would be helpful to address this question, as the responsiveness of CD8+ T
cells for these particular factors could be tested.
The mechanistic events behind the chemokine-­‐dependent increase in contact duration have
been partially characterized. Friedman et al. suggested that chemokine contacts transiently
tether CD8+ T cells to chemokine-­‐presenting DCs in a LFA-­‐1 dependent fashion (96). It is well
established that chemokine receptor activation can increase the affinity of LFA1 for ICAM1 (98,
99), which would augment the stability of cell-­‐cell contacts. Besides integrin-­‐mediated
adhesiveness, Friedman et al. observed that the CD8+ T cell acquired a polarized morphology
and the T cell receptor (TCR) localized towards the contact site, whereby the hyperpolarized T
cell gained enhanced sensitivity to antigen at the leading edge (96). This might be a mechanism
that has a costimulatory effect on the induction of CD8+ T cell responses and may also play a
role in CCL17-­‐mediated contact duration. They found no influence of CCL17 on tethering of
CD8+ T cells, but this could be due to the fact that they used untreated CD8+ T cells that do not
express CCR4 and could therefore not respond to CCL17. An additional mechanism that could
increase contact duration is the recruitment of certain chemokine receptors to the
immunological synapse (IS). CCR4 belongs to the so-­‐called subordinate receptors that are
recruited to the IS and thus become ignorant to chemokine gradients (100, 101). By this
mechanism, more stable contacts between DC and CD8+ T cell might be formed and this would
permit more extensive scanning of the DC surface. This CCL17-­‐dependent increase in CD8+ T
cell – DC contact duration might also account for higher numbers of CD8+ T cells in splenic T
cell zones evidenced by histology, as CD8+ T cells might accumulate due to a prolonged
interaction with DCs.
In summary, CCL17 may increase the efficiency of CD8+ T cell responses on the one hand by
mediating the preferential scanning of “relevant” DCs that provide both antigenic and
costimulatory signals, and are therefore more likely to induce an efficient immune response
than unlicensed DCs. On the other hand, CCL17 prolongs CD8+ T cell -­‐ DC contact duration. As
CCL17 signals can be considered as indicators of the presence of mature, antigen-­‐presenting
DCs, it is reasonable that they increase the accuracy with which CD8+ T cells scan these DCs for
the presence of their specific antigen. Thereby CCL17 expression further enhances the
likeliness of efficient T cell activation. In vivo cytotoxicity assays clearly demonstrate the
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impact of these chemokine signals on cross-­‐priming, as the cytotoxic capacity of CD8+ T cells
was reduced by 50-­‐60% in CCL17-­‐ and CCR4-­‐deficient mice.
5.2 Synergistic effect of classical and NKT cell-­mediated DC licensing
5.2.1 Distinct regulation of classical and NKT cell-­mediated cross-­priming
The data presented in this study identify CCL17 and CCR4 as the second chemokine –
chemokine receptor pair that regulates cross-­‐priming besides CCR5 and its ligands CCL3, CCL4
and CCL5. DC licensing by CD4+ TH cells in the presence of the TLR9 ligand CpG induces
expression of CCR5 ligands (57) whereas expression of CCR4 and its ligands is induced by the
presence of glycolipid antigens through activation of NKT cells. Moreover, CD4+ TH cells were
dispensable for NKT cell-­‐mediated cross-­‐priming as demonstrated in MHCII-­‐deficient mice,
which were able to generate a CD8+ T cell response as efficient as were wild-­‐type mice after
immunization with OVA plus αGalCer, suggesting that classical and NKT cell-­‐mediated cross-­‐
priming operate separately. Histological analysis revealed that CD8+ T cells are attracted in a
CCR4-­‐dependent fashion in NKT cell-­‐mediated but not classical cross-­‐priming. On the other
hand, CCR5 attracted CD8+ T cells in classical but not NKT cell-­‐mediated cross-­‐priming.
Furthermore, the cytotoxic T cell response of CCR5-­‐deficient mice was as efficient as that of
wild-­‐type mice after injection of OVA plus αGalCer, confirming that CCR5 is not involved in NKT
cell-­‐mediated cross-­‐priming. Additionally, CCL17 expression is not influenced by CpG-­‐induced
TLR9 stimulation, as similar percentages of DCs expressed comparable levels of CCL17 after
injection of OVA plus αGalCer with or without CpG. These results indicate that the
chemokines, which are induced by classical and NKT cell-­‐mediated DC licensing do not
influence each other’s expression. Thus one can state that classical and NKT cell-­‐mediated
cross-­‐priming are regulated by distinct chemokine pathways that do not influence each other
and that both ensure improved attraction and / or retention of CD8+ T cells.
5.2.2 Synergistic effect of classical and NKT cell-­mediated cross-­priming on CD8+ T
cell responses
The fact that classical and NKT cell-­‐mediated cross-­‐priming are regulated by different
chemokines raises the question what advantage might lie in the induction of two distinct
chemokine pathways. One possible explanation could be that they might act in a synergistic
manner to further enhance T cell activation, as successful antigen-­‐presentation to both CD4+ TH
65
and NKT cells would emphasize the relevance of the presented antigen. To address this
hypothesis, I analyzed the cytotoxic T cell response after the simultaneous activation of both
classical and NKT cell-­‐mediated cross-­‐priming by co-­‐injecting of OVA with αGalCer and CpG.
Interestingly, the CD8+ T cell response was highly improved compared to coinjection with
αGalCer or CpG alone, and this could be observed both after intravenous injection in the
spleen as well as in draining lymph nodes after subcutaneous injection, which is especially
relevant for hypothetic application for vaccination.
These results might be relevant for application in vaccination strategies and tumor therapy. So
far, both TLR ligands and NKT cell ligands alone have been identified as valuable adjuvants for
vaccinations against pathogens as well as tumors (102,103,104). αGalCer is already being
employed as an adjuvant in tumor immunotherapy (105, 72-­‐74), in which the transfer of
αGalCer-­‐loaded DCs has so far provided the best results. However, the results are not yet
optimal in terms of disease amelioration and may be further improved by the simultaneous
application of CpG. Indeed, some reports have indeed described a beneficial effect of the
combined application of αGalCer and TLR ligands (70, 106). For other diseases in which NKT
cells are involved like malaria, Borrelia burgdorferi or Sphingomonas infections, it seems likely
that pathogens provide a range of microbial agents and would activate both pathways.
Thus, to be able to optimize treatment strategies, the events underlying enhanced CD8+ T cell
responses after the combination of αGalCer and CpG injection were investigated. Obvious
factors that could be involved are increased levels of costimulatory molecules, cytokines and
chemokines. Concerning signal 2, it has been described that the expression of costimulatory
molecules is further increased after co-­‐injection of αGalCer with various TLR ligands, including
CpG, compared to injection of one adjuvant alone (106). In that way, DCs could provide more
costimulatory signals and improve CD8+ T cell activation. Nevertheless, the results presented in
this study demonstrate that chemokine signals are at least as important for efficient CD8+ T cell
responses as costimulatory signals, as cytotoxic T cell responses were reduced by around 60%
due to lack of chemokines. The exact contribution of costimulatory signals versus chemokine
signals to cross-­‐priming has not yet been investigated, but experiments could be performed
using CD80/86-­‐deficient mice to address this question.
However, the present study focused on the contribution of chemokines to enhanced CD8+ T
cell responses after the combined activation of classical and NKT cell-­‐mediated DC licensing.
First, the attraction and accumulation of CD8+ T cells was investigated. Indeed, increased
numbers of CD8+ T cells accumulated in splenic T cell zones after injection of OVA with αGalCer
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plus CpG compared to coinjection with either adjuvant alone, confirming the importance of
chemokine signals for the synergistic effect. As a first approach to answer the question how
this enhanced migratory effect is mediated, chemokine production by DCs was investigated.
The results revealed that DCs produced CCL17, CCL3 and CCL5 after injection of OVA plus
αGalCer plus CpG. Interestingly, the same DCs that produce CCL17 co-­‐expressed the CCR5
ligands whereas the remaining DCs produced only low levels of CCL3 and CCL5. These results
raised the question how chemokine production is orchestrated in vivo. As shown in the
present study, the induction of chemokine expression is linked to cell-­‐cell interactions during
DC licensing, but soluble factors such as IL-­‐4, IL-­‐13 and TNFα were able to induce chemokine
expression in vitro. Thus, cell-­‐cell contact between a CD4+ TH or an NKT cell with a DC might
induce chemokine expression through the upregulation of cytokines rather than in a cell-­‐cell
contact-­‐dependent fashion. In this case, all secreted cytokines would act on the same DCs,
leading to the uniform production of several chemokines by the same cells. However, only a
subset of DCs expresses these chemokines. One possible explanation could be that the effect
of the secreted cytokines could be restricted to a certain area, so that only DCs in that area
would respond by expressing chemokines. Another explanation could be that only a subset of
DCs is responsive to the factors that induce chemokine expression. This question could be
addressed by staining for IL-­‐4-­‐ and TNFα-­‐receptors on CCL17-­‐expressing or non-­‐expressing
DCs. Furthermore, DCs might be rendered responsive to the critical signals during licensing,
which could be investigated by staining for the relevant receptors before and after licensing.
Furthermore, it would be necessary to test the requirement of cell-­‐cell contact for CCL17
expression by analyzing the CCL17 expression of licensed or unlicensed DCs. To this end, CD1d-­‐
deficient and –sufficient DCs from CD1d-­‐/-­‐ / bm1 mixed bone marrow chimeras could be
sorted after injection of OVA plus αGalCer, and they could be analyzed for CCL17 expression by
real-­‐time PCR. CCL17 expression by CD1d-­‐deficient DCs would argue against the requirement
for cell-­‐cell contact in inducing chemokine expression. Furthermore, it will be interesting to
investigate chemokine production by the licensing cells, namely CD4+ TH and NKT cells.
Castellino et al. described the expression of CCL4 in classical licensing. As the present study did
not detect the expression of CCL4 by DCs, the source of this chemokine could be CD4+ TH cells.
In parallel, NKT cells produced the second CCR4 ligand CCL22. Thus, not only DCs but also the
licensing T cells seem to contribute to the attraction of naïve CD8+ T cells.
My results suggest that CD8+ T cells expressing CCR4 and CCR5 are attracted towards the same
DCs. As mentioned above, this concept is problematic in a way that an overabundance of
attracted T cells could inhibit T cell activation rather than enhancing CD8+ T cell responses.
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However, production of both CCR4 and CCR5 ligands by the same DC might facilitate T cell
attraction as competing chemokine signals could distract CD8+ T cells and even impair their
directional migration. Ricart et al. (107) demonstrated that DCs stopped their directional
migration when they were exposed to two equipotent perpendicular chemokine gradients of
CCL19 and CXCL12 and limited their migration to a zone between the gradients. Nevertheless,
whether this is also true for CD8+ T cells remains unclear.
However, it will be interesting to characterize the expression of chemokine receptors on CD8+
T cells. As chemokine receptor expression seems to be upregulated by soluble signals, it can be
expected that CD8+ T cells coexpress both receptors. Nevertheless, only a small percentage of
CD8+ T cells upregulated CCR4, raising the question if the critical signal for CCR4 induction only
reaches a small number of CD8+ T cells, or if some CD8+ T cells are not responsive to this agent.
Whether this is also the case for CCR5 expression and by which cells CCR4 and CCR5 are
expressed needs to be determined by flow-­‐cytometric analysis. These experiments might
clarify whether their synergistic effect is mediated by attraction of higher numbers of
CCR4+CCR5+ CD8+ T cells, or if a mixture of CCR4+ and CCR5+ CD8+ T cell subsets accumulates.
The latter would raise questions about the prerequisites for the expression of chemokine
receptors by CD8+ T cells, and these require further investigations.
In summary, the results obtained during my thesis work suggest that the synergistic effect of
classical and NKT cell-­‐mediated cross-­‐priming is at least in part mediated by migratory cues.
However, the exact mechanisms underlying the enhanced CD8+ T cell responses require
further investigations, and the contributions of antigenic, costimulatory, cytokine and
chemokine signals need to be determined. Clarifying these mechanisms could help to improve
vaccination strategies and will further the understanding of chemokine-­‐regulated cell
interactions.
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6 Summary
The detection and destruction of virus-­‐infected or tumor cells is the main task of CD8+ T cells.
Their activation needs to be tightly regulated to avoid the misguided killing of healthy cells. To
this end, activation of CD8+ T cells requires not only antigenic signals but also additional
costimulatory signals provided by mature DCs. The process that renders DCs capable of cross-­‐
priming has been termed DC licensing and can be induced by antigen-­‐specific interactions with
CD4+ TH cells. As the frequencies of specific antigen-­‐bearing DCs and the relevant antigen-­‐
specific naïve CD4+ and CD8+ T cells are low, the involvement of chemokines as regulators of
cell – cell interactions seems likely. Indeed, CCR5 has been described to be upregulated on
naïve CD8+ T cells, thereby attracting these cells to the site of DC – CD4+ TH cell interactions,
where the CCR5 ligands CCL3 and CCL4 are produced. Recently it has been established that not
only CD4+ TH cells but also NKT cells can provide help for DC maturation, but the exact
mechanisms remain unclear.
The present study characterizes NKT cell-­‐mediated DC licensing and presents a new aspect of
DC licensing by demonstrating that the presentation of glycolipid antigens by DCs to NKT cells
resulted not only in DC maturation but also in the expression of the chemokine CCL17 by the
antigen-­‐presenting DC. Moreover, it establishes that the induction of this chemokine is a
critical component of DC licensing and is crucial for the generation of efficient CD8+ T cell
responses, as the lack of CCL17 or its receptor CCR4 strongly impaired cross-­‐priming. Several
possible mechanisms for impaired cross-­‐priming were investigated. Published findings of
others made an effect on DCs and NKT cells most likely, but this was not the case. Instead,
CCL17 increased the efficiency of cross-­‐priming by acting directly on CD8+ T cells. Several
experimental approaches revealed that CD8+ T cells that had upregulated CCR4 in response to
a yet unknown factor were attracted by CCL17 towards licensed DCs. Additionally, CCL17
increased the DC – CD8+ T cell contact duration, thus promoting efficient scanning of the DC
surface and enhancing the chances of efficient cross-­‐presentation.
These results identify CCL17 – CCR4 as a second chemokine – chemokine receptor pair that
regulates cross-­‐priming. Furthermore, they uncovered a previously unrecognized role of CCL17
and CCR4 in cytotoxic T cell responses. Finally, these results demonstrated that the two
chemokine mechanisms that regulate classical and NKT cell-­‐mediated cross-­‐priming act in a
synergistic manner by further increasing the efficiency of CD8+ T cell responses. Understanding
the molecular mechanism of this synergistic effect may help improving vaccination strategies.
69
7 References
1. Curtsinger, J. M., C. S. Schmidt, et al. (1999). "Inflammatory cytokines provide a third
signal for activation of naive CD4+ and CD8+ T cells." J Immunol 162(6): 3256-­‐62.
2. Bevan, M.J. (1976). "Cross-­‐priming for a secondary cytotoxic response to minor H
antigens with H-­‐2 congenic cells which do not cross-­‐react in the cytotoxic assay.“
J Exp Med 143(5):1283-­‐8
3. Houde, M., S. Bertholet, et al. (2003). "Phagosomes are competent organelles for
antigen cross-­‐presentation." Nature 425(6956): 402-­‐6.
4. Burgdorf, S., A. Kautz, et al. (2007). "Distinct pathways of antigen uptake and
intracellular routing in CD4 and CD8 T cell activation." Science 316(5824): 612-­‐6.
5. Saveanu, L., O. Carroll, et al. (2009). "IRAP identifies an endosomal compartment
required for MHC class I cross-­‐presentation." Science 325(5937): 213-­‐7.
6. Burgdorf, S., C. Scholz, et al. (2008). "Spatial and mechanistic separation of cross-­‐
presentation and endogenous antigen presentation." Nat Immunol 9(5): 558-­‐66.
7. Touret, N., P. Paroutis, et al. (2005). "Quantitative and dynamic assessment of the
contribution of the ER to phagosome formation." Cell 123(1): 157-­‐70.
8. Shortman, K. and W. R. Heath (2010) "The CD8+ dendritic cell subset." Immunol Rev
234(1): 18-­‐31.
9. Poulin, L. F., M. Salio, et al. "Characterization of human DNGR-­‐1+ BDCA3+ leukocytes as
putative equivalents of mouse CD8alpha+ dendritic cells." J Exp Med 207(6): 1261-­‐71.
10. Crozat, K., R. Guiton, et al. "The XC chemokine receptor 1 is a conserved selective
marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells." J Exp
Med 207(6): 1283-­‐92.
11. Hon, H., A. Oran, et al. (2005). "B lymphocytes participate in cross-­‐presentation of
antigen following gene gun vaccination." J Immunol 174(9): 5233-­‐42.
12. Brandes, M., K. Willimann, et al. (2005). "Professional antigen-­‐presentation function by
human gammadelta T Cells." Science 309(5732): 264-­‐8.
13. Tvinnereim, A. R., S. E. Hamilton, et al. (2004). "Neutrophil involvement in cross-­‐
priming CD8+ T cell responses to bacterial antigens." J Immunol 173(3): 1994-­‐2002.
14. Ramirez, M. C. and L. J. Sigal (2002). "Macrophages and dendritic cells use the cytosolic
pathway to rapidly cross-­‐present antigen from live, vaccinia-­‐infected cells." J Immunol
169(12): 6733-­‐42.
15. Limmer, A., J. Ohl, et al. (2000). "Efficient presentation of exogenous antigen by liver
endothelial cells to CD8+ T cells results in antigen-­‐specific T-­‐cell tolerance." Nat Med
70
6(12): 1348-­‐54.
16. Curtsinger, J. M., C. M. Johnson, et al. (2003). "CD8 T cell clonal expansion and
development of effector function require prolonged exposure to antigen,
costimulation, and signal 3 cytokine." J Immunol 171(10): 5165-­‐71.
17. Mescher, M. F., J. M. Curtsinger, et al. (2006). "Signals required for programming
effector and memory development by CD8+ T cells." Immunol Rev 211: 81-­‐92.
18. Banchereau, J. and R. M. Steinman (1998). "Dendritic cells and the control of
immunity." Nature 392(6673): 245-­‐52.
19. Smith, C. M., N. S. Wilson, et al. (2004). "Cognate CD4(+) T cell licensing of dendritic
cells in CD8(+) T cell immunity." Nat Immunol 5(11): 1143-­‐8.
20. Iwasaki, A. and R. Medzhitov "Regulation of adaptive immunity by the innate immune
system." Science 327(5963): 291-­‐5.
21. Bennett, S. R., F. R. Carbone, et al. (1998). "Help for cytotoxic-­‐T-­‐cell responses is
mediated by CD40 signalling." Nature 393(6684): 478-­‐80.
22. Cella, M., D. Scheidegger, et al. (1996). "Ligation of CD40 on dendritic cells triggers
production of high levels of interleukin-­‐12 and enhances T cell stimulatory capacity: T-­‐T
help via APC activation." J Exp Med 184(2): 747-­‐52.
23. Shedlock, D. J. and H. Shen (2003). "Requirement for CD4 T cell help in generating
functional CD8 T cell memory." Science 300(5617): 337-­‐9.
24. Sun, J. C. and M. J. Bevan (2003). "Defective CD8 T cell memory following acute
infection without CD4 T cell help." Science 300(5617): 339-­‐42.
25. Morita, M., K. Motoki, et al. (1995). "Structure-­‐activity relationship of alpha-­‐
galactosylceramides against B16-­‐bearing mice." J Med Chem 38(12): 2176-­‐87.
26. Hermans, I. F., J. D. Silk, et al. (2003). "NKT cells enhance CD4+ and CD8+ T cell
responses to soluble antigen in vivo through direct interaction with dendritic cells." J
Immunol 171(10): 5140-­‐7.
27. Fujii, S., K. Shimizu, et al. (2003). "Activation of natural killer T cells by alpha-­‐
galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and
thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a
coadministered protein." J Exp Med 198(2): 267-­‐79.
28. Fujii, S., K. Liu, et al. (2004). "The linkage of innate to adaptive immunity via maturing
dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and
CD80/86 costimulation." J Exp Med 199(12): 1607-­‐18.
29. Godfrey, D. I., S. Stankovic, et al. "Raising the NKT cell family." Nat Immunol 11(3): 197-­‐
206.
71
30. Kawano, T., J. Cui, et al. (1997). "CD1d-­‐restricted and TCR-­‐mediated activation of
valpha14 NKT cells by glycosylceramides." Science 278(5343): 1626-­‐9.
31. Kobayashi, E., K. Motoki, et al. (1995). "KRN7000, a novel immunomodulator, and its
antitumor activities." Oncol Res 7(10-­‐11): 529-­‐34.
32. Miyamoto, K., S. Miyake, et al. (2001). "A synthetic glycolipid prevents autoimmune
encephalomyelitis by inducing TH2 bias of natural killer T cells." Nature 413(6855): 531-­‐
4.
33. Kinjo, Y., D. Wu, et al. (2005). "Recognition of bacterial glycosphingolipids by natural
killer T cells." Nature 434(7032): 520-­‐5.
34. Kinjo, Y., E. Tupin, et al. (2006). "Natural killer T cells recognize diacylglycerol antigens
from pathogenic bacteria." Nat Immunol 7(9): 978-­‐86.
35. Zhou, D., J. Mattner, et al. (2004). "Lysosomal glycosphingolipid recognition by NKT
cells." Science 306(5702): 1786-­‐9.
36. Darmoise, A., S. Teneberg, et al. "Lysosomal alpha-­‐galactosidase controls the
generation of self lipid antigens for natural killer T cells." Immunity 33(2): 216-­‐28.
37. Mattner, J., K. L. Debord, et al. (2005). "Exogenous and endogenous glycolipid antigens
activate NKT cells during microbial infections." Nature 434(7032): 525-­‐9.
38. Coquet, J. M., S. Chakravarti, et al. (2008). "Diverse cytokine production by NKT cell
subsets and identification of an IL-­‐17-­‐producing CD4-­‐NK1.1-­‐ NKT cell population." Proc
Natl Acad Sci U S A 105(32): 11287-­‐92.
39. Zlotnik, A. and O. Yoshie (2000). "Chemokines: a new classification system and their
role in immunity." Immunity 12(2): 121-­‐7.
40. Bachmann, M. F., M. Kopf, et al. (2006). "Chemokines: more than just road signs." Nat
Rev Immunol 6(2): 159-­‐64.
41. Rot, A. and U. H. von Andrian (2004). "Chemokines in innate and adaptive host defense:
basic chemokinese grammar for immune cells." Annu Rev Immunol 22: 891-­‐928.
42. Lieberam, I. and I. Forster (1999). "The murine beta-­‐chemokine TARC is expressed by
subsets of dendritic cells and attracts primed CD4+ T cells." Eur J Immunol 29(9): 2684-­‐
94.
43. Imai, T., D. Chantry, et al. (1998). "Macrophage-­‐derived chemokine is a functional
ligand for the CC chemokine receptor 4." J Biol Chem 273(3): 1764-­‐8.
44. Campbell, J. J., G. Haraldsen, et al. (1999). "The chemokine receptor CCR4 in vascular
recognition by cutaneous but not intestinal memory T cells." Nature 400(6746): 776-­‐80.
45. Alferink, J., I. Lieberam, et al. (2003). "Compartmentalized production of CCL17 in vivo:
strong inducibility in peripheral dendritic cells contrasts selective absence from the
72
spleen." J Exp Med 197(5): 585-­‐99.
46. Horikawa, T., T. Nakayama, et al. (2002). "IFN-­‐gamma-­‐inducible expression of thymus
and activation-­‐regulated chemokine/CCL17 and macrophage-­‐derived chemokine/CCL22
in epidermal keratinocytes and their roles in atopic dermatitis." Int Immunol 14(7): 767-­‐
73.
47. Iellem, A., M. Mariani, et al. (2001). "Unique chemotactic response profile and specific
expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T
cells." J Exp Med 194(6): 847-­‐53.
48. Inngjerdingen, M., B. Damaj, et al. (2000). "Human NK cells express CC chemokine
receptors 4 and 8 and respond to thymus and activation-­‐regulated chemokine,
macrophage-­‐derived chemokine, and I-­‐309." J Immunol 164(8): 4048-­‐54.
49. Clemetson, K. J., J. M. Clemetson, et al. (2000). "Functional expression of CCR1, CCR3,
CCR4, and CXCR4 chemokine receptors on human platelets." Blood 96(13): 4046-­‐54.
50. Kawasaki, S., H. Takizawa, et al. (2001). "Intervention of thymus and activation-­‐
regulated chemokine attenuates the development of allergic airway inflammation and
hyperresponsiveness in mice." J Immunol 166(3): 2055-­‐62.
51. Bonecchi, R., M. Locati, et al. (2004). "Differential recognition and scavenging of native
and truncated macrophage-­‐derived chemokine (macrophage-­‐derived chemokine/CC
chemokine ligand 22) by the D6 decoy receptor." J Immunol 172(8): 4972-­‐6.
52. Borchers, M. T., T. Ansay, et al. (2002). "In vitro assessment of chemokine receptor-­‐
ligand interactions mediating mouse eosinophil migration." J Leukoc Biol 71(6): 1033-­‐
41.
53. Stutte, S., T. Quast, et al. "Requirement of CCL17 for CCR7-­‐ and CXCR4-­‐dependent
migration of cutaneous dendritic cells." Proc Natl Acad Sci U S A 107(19): 8736-­‐41.
54. Forster, R., A. Schubel, et al. (1999). "CCR7 coordinates the primary immune response
by establishing functional microenvironments in secondary lymphoid organs." Cell
99(1): 23-­‐33.
55. Sallusto, F., P. Schaerli, et al. (1998). "Rapid and coordinated switch in chemokine
receptor expression during dendritic cell maturation." Eur J Immunol 28(9): 2760-­‐9.
56. Willimann, K., D. F. Legler, et al. (1998). "The chemokine SLC is expressed in T cell areas
of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7."
Eur J Immunol 28(6): 2025-­‐34.
57. Castellino, F., A. Y. Huang, et al. (2006). "Chemokines enhance immunity by guiding
naive CD8+ T cells to sites of CD4+ T cell-­‐dendritic cell interaction." Nature 440(7086):
890-­‐5.
73
58. Hugues, S., A. Scholer, et al. (2007). "Dynamic imaging of chemokine-­‐dependent CD8+ T
cell help for CD8+ T cell responses." Nat Immunol 8(9): 921-­‐30.
59. Du, W., S. S. Kulkarni, et al. (2007). "Efficient, one-­‐pot syntheses of biologically active
alpha-­‐linked glycolipids." Chem Commun (Camb)(23): 2336-­‐8.
60. Long, X., S. Deng, et al. (2007). "Synthesis and evaluation of stimulatory properties of
Sphingomonadaceae glycolipids." Nat Chem Biol 3(9): 559-­‐64.
61. Lukacs-­‐Kornek, V., S. Burgdorf, et al. (2008). "The kidney-­‐renal lymph node-­‐system
contributes to cross-­‐tolerance against innocuous circulating antigen." J Immunol
180(2): 706-­‐15.
62. Heymann, F., C. Meyer-­‐Schwesinger, et al. (2009). "Kidney dendritic cell activation is
required for progression of renal disease in a mouse model of glomerular injury." J Clin
Invest 119(5): 1286-­‐97.
63. Wolf, S. F., P. A. Temple, et al. (1991). "Cloning of cDNA for natural killer cell
stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and
natural killer cells." J Immunol 146(9): 3074-­‐81.
64. Schmitz, J., A. Owyang, et al. (2005). "IL-­‐33, an interleukin-­‐1-­‐like cytokine that signals
via the IL-­‐1 receptor-­‐related protein ST2 and induces T helper type 2-­‐associated
cytokines." Immunity 23(5): 479-­‐90.
65. Soumelis, V., P. A. Reche, et al. (2002). "Human epithelial cells trigger dendritic cell
mediated allergic inflammation by producing TSLP." Nat Immunol 3(7): 673-­‐80.
66. Mattner, J., P. B. Savage, et al. (2008). "Liver autoimmunity triggered by microbial
activation of natural killer T cells." Cell Host Microbe 3(5): 304-­‐15.
67. Smyth, M. J., K. Y. Thia, et al. (2000). "Differential tumor surveillance by natural killer
(NK) and NKT cells." J Exp Med 191(4): 661-­‐8.
68. Crowe, N. Y., M. J. Smyth, et al. (2002). "A critical role for natural killer T cells in
immunosurveillance of methylcholanthrene-­‐induced sarcomas." J Exp Med 196(1): 119-­‐
27.
69. Stober, D., I. Jomantaite, et al. (2003). "NKT cells provide help for dendritic cell-­‐
dependent priming of MHC class I-­‐restricted CD8+ T cells in vivo." J Immunol 170(5):
2540-­‐8.
70. Silk, J. D., I. F. Hermans, et al. (2004). "Utilizing the adjuvant properties of CD1d-­‐
dependent NK T cells in T cell-­‐mediated immunotherapy." J Clin Invest 114(12): 1800-­‐
11.
71. Gonzalez-­‐Aseguinolaza, G., L. Van Kaer, et al. (2002). "Natural killer T cell ligand alpha-­‐
galactosylceramide enhances protective immunity induced by malaria vaccines." J Exp
74
Med 195(5): 617-­‐24.
72. Chang, D. H., K. Osman, et al. (2005). "Sustained expansion of NKT cells and antigen-­‐
specific T cells after injection of alpha-­‐galactosyl-­‐ceramide loaded mature dendritic
cells in cancer patients." J Exp Med 201(9): 1503-­‐17.
73. Uchida, T., S. Horiguchi, et al. (2008). "Phase I study of alpha-­‐galactosylceramide-­‐pulsed
antigen presenting cells administration to the nasal submucosa in unresectable or
recurrent head and neck cancer." Cancer Immunol Immunother 57(3): 337-­‐45.
74. Nieda, M., M. Okai, et al. (2004). "Therapeutic activation of Valpha24+Vbeta11+ NKT
cells in human subjects results in highly coordinated secondary activation of acquired
and innate immunity." Blood 103(2): 383-­‐9.
75. Fischer, F. R., Y. Luo, et al. (2001). "RANTES-­‐induced chemokine cascade in dendritic
cells." J Immunol 167(3): 1637-­‐43.
76. Kohout, T. A., S. L. Nicholas, et al. (2004). "Differential desensitization, receptor
phosphorylation, beta-­‐arrestin recruitment, and ERK1/2 activation by the two
endogenous ligands for the CC chemokine receptor 7." J Biol Chem 279(22): 23214-­‐22.
77. Xiao, T., H. Fujita, et al. (2003). "Thymus and activation-­‐regulated chemokine
(TARC/CCL17) produced by mouse epidermal Langerhans cells is upregulated by TNF-­‐
alpha and IL-­‐4 and downregulated by IFN-­‐gamma." Cytokine 23(4-­‐5): 126-­‐32.
78. Fujita, H., A. Asahina, et al. (2005). "Differential production of Th1-­‐ and Th2-­‐type
chemokines by mouse Langerhans cells and splenic dendritic cells." J Invest Dermatol
124(2): 343-­‐50.
79. Kakinuma, T., K. Nakamura, et al. (2002). "IL-­‐4, but not IL-­‐13, modulates TARC (thymus
and activation-­‐regulated chemokine)/CCL17 and IP-­‐10 (interferon-­‐induced protein of
10kDA)/CXCL10 release by TNF-­‐alpha and IFN-­‐gamma in HaCaT cell line." Cytokine
20(1): 1-­‐6.
80. Yu, B., T. Koga, et al. (2002). "Differential regulation of thymus-­‐ and activation-­‐
regulated chemokine induced by IL-­‐4, IL-­‐13, TNF-­‐alpha and IFN-­‐gamma in human
keratinocyte and fibroblast." J Dermatol Sci 30(1): 29-­‐36.
81. Yoshimoto, T. and W. E. Paul (1994). "CD4pos, NK1.1pos T cells promptly produce
interleukin 4 in response to in vivo challenge with anti-­‐CD3." J Exp Med 179(4): 1285-­‐
95.
82. Lee, H., C. Hong, et al. (2009). "The presence of CD8+ invariant NKT cells in mice." Exp
Mol Med 41(12): 866-­‐72.
83. Gumperz, J. E., S. Miyake, et al. (2002). "Functionally distinct subsets of CD1d-­‐restricted
natural killer T cells revealed by CD1d tetramer staining." J Exp Med 195(5): 625-­‐36.
75
84. McIlroy, A., G. Caron, et al. (2006). "Histamine and prostaglandin E up-­‐regulate the
production of Th2-­‐attracting chemokines (CCL17 and CCL22) and down-­‐regulate
IFNgamma-­‐induced CXCL10 production by immature human dendritic cells."
Immunology 117(4): 507-­‐16.
85. Cella, M., D. Scheidegger, et al. (1996). "Ligation of CD40 on dendritic cells triggers
production of high levels of interleukin-­‐12 and enhances T cell stimulatory capacity: T-­‐T
help via APC activation." J Exp Med 184(2): 747-­‐52.
86. Trifilo, M. J. and T. E. Lane (2004). "The CC chemokine ligand 3 regulates
CD11c+CD11b+CD8alpha-­‐ dendritic cell maturation and activation following viral
infection of the central nervous system: implications for a role in T cell activation."
Virology 327(1): 8-­‐15.
87. Jimenez, F., M. P. Quinones, et al. "CCR2 plays a critical role in dendritic cell
maturation: possible role of CCL2 and NF-­‐kappa B." J Immunol 184(10): 5571-­‐81.
88. Matsuda, J. L., T. Mallevaey, et al. (2008). "CD1d-­‐restricted iNKT cells, the 'Swiss-­‐Army
knife' of the immune system." Curr Opin Immunol 20(3): 358-­‐68.
89. Le Bon, A., V. Durand, et al. (2006). "Direct stimulation of T cells by type I IFN enhances
the CD8+ T cell response during cross-­‐priming." J Immunol 176(8): 4682-­‐9.
90. McColl, S. R. (2002). "Chemokines and dendritic cells: a crucial alliance." Immunol Cell
Biol 80(5): 489-­‐96.
91. Locati, M., K. Otero, et al. (2002). "The chemokine system: tuning and shaping by
regulation of receptor expression and coupling in polarized responses." Allergy 57(11):
972-­‐82.
92. Smithgall, M. D., M. R. Comeau, et al. (2008). "IL-­‐33 amplifies both Th1-­‐ and Th2-­‐type
responses through its activity on human basophils, allergen-­‐reactive Th2 cells, iNKT and
NK cells." Int Immunol 20(8): 1019-­‐30.
93. Bajenoff, M., N. Glaichenhaus, et al. (2008). "Fibroblastic reticular cells guide T
lymphocyte entry into and migration within the splenic T cell zone." J Immunol 181(6):
3947-­‐54.
94. Umetsu, D. T. and R. H. Dekruyff "Natural killer T cells are important in the
pathogenesis of asthma: the many pathways to asthma." J Allergy Clin Immunol
125(5): 975-­‐9.
95. Sekiya, T., H. Yamada, et al. (2002). "Increased levels of a TH2-­‐type CC chemokine
thymus and activation-­‐regulated chemokine (TARC) in serum and induced sputum of
asthmatics." Allergy 57(2): 173-­‐7.
96. Friedman, R. S., J. Jacobelli, et al. (2006). "Surface-­‐bound chemokines capture and
76
prime T cells for synapse formation." Nat Immunol 7(10): 1101-­‐8.
97. Iezzi, G., K. Karjalainen, et al. (1998). "The duration of antigenic stimulation determines
the fate of naive and effector T cells." Immunity 8(1): 89-­‐95.
98. Campbell, J. J., E. P. Bowman, et al. (1998). "6-­‐C-­‐kine (SLC), a lymphocyte adhesion-­‐
triggering chemokine expressed by high endothelium, is an agonist for the MIP-­‐3beta
receptor CCR7." J Cell Biol 141(4): 1053-­‐9.
99. Kim, M., C. V. Carman, et al. (2003). "Bidirectional transmembrane signaling by
cytoplasmic domain separation in integrins." Science 301(5640): 1720-­‐5.
100. Molon, B., G. Gri, et al. (2005). "T cell costimulation by chemokine receptors." Nat
Immunol 6(5): 465-­‐71.
101. Bromley, S. K., D. A. Peterson, et al. (2000). "Cutting edge: hierarchy of chemokine
receptor and TCR signals regulating T cell migration and proliferation." J Immunol
165(1): 15-­‐9.
102. Cerundolo, V., J. D. Silk, et al. (2009). "Harnessing invariant NKT cells in vaccination
strategies." Nat Rev Immunol 9(1): 28-­‐38.
103. Terabe, M. and J. A. Berzofsky (2008). "The role of NKT cells in tumor immunity." Adv
Cancer Res 101: 277-­‐348.
104. Liu, K., J. Idoyaga, et al. (2005). "Innate NKT lymphocytes confer superior adaptive
immunity via tumor-­‐capturing dendritic cells." J Exp Med 202(11): 1507-­‐16.
105. Uchida, T., S. Horiguchi, et al. (2008). "Phase I study of alpha-­‐galactosylceramide-­‐
pulsed antigen presenting cells administration to the nasal submucosa in unresectable
or recurrent head and neck cancer." Cancer Immunol Immunother 57(3): 337-­‐45.
106. Hermans, I. F., J. D. Silk, et al. (2007). "Dendritic cell function can be modulated
through cooperative actions of TLR ligands and invariant NKT cells." J Immunol 178(5):
2721-­‐9.
107. Ricart, B. G., B. John, et al. "Dendritic cells distinguish individual chemokine signals
through CCR7 and CXCR4." J Immunol 186(1): 53-­‐61.
77
8 Abbreveations
αGalCer α-­‐galactosylceramide
APC antigen-­‐presenting cell
BM bone marrow
Bp basepair
BSA Bovine serum albumin
CCL Chemokine ligand
CCR Chemokine receptor
CD Cluster of differentiation
CFSE 5,6-­‐Carboxy-­‐Succinimidyl-­‐Fluoresceine-­‐Ester
CTL cytotoxic T lymphocyte
DC Dendritic cell
FACS Fluorescence activated cell sorting
FCS Fetal Calf Serum
FITC Fluorescein-­‐5-­‐isothiocyanate
FRC Fibroblastic reticular cell
HEV High endothelial venules
ICAM Intracellular adhesion molecule
IFN Interferone
IL Interleukine
NKT cell Natural killer T cell
i.p. intraperitoneal
IS Immunological Synapse
i.v. intravenous
LFA-­‐1 Leukocyte functional antigen 1
LN Lymphnode
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LPS Lipopolysaccharide
MACS Magnetic activated cell sorting
MFI Mean fluorescence intensity
MHC Major histocompatibility complex
OPD O-­‐phenylendiamin
OVA Ovalbumin
PFA Paraformaldehyde
RAG Recombination activating gene
RT PCR real-­‐time polymerase chain reaction
s.c. subcutaneous
SLO Secondary lymphoid organ
TARC Thymus and activation-­‐regulated chemokine
TCR T cell receptor
TLR Toll-­‐like receptor
TNF Tumor necrosis factor
TH T helper cell
